   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 1 
 
 
Evaluating the Safety and E ffectiveness of the Omnipod 
Horizon ™ Automated Glucose Control  System  in Patients with 
Type 1 D iabetes  
 
 
IDE G190270  
Version  5.0 
November 1 2, 2020 
 
 
Insulet Corporation  
100 Nagog Park  
Acton , MA [ZIP_CODE] 
 
 
 
 
Confidentiality Statement:  
The information in this document contains trade secrets and commercial information that are 
privileged or confidential and may not be disclosed unless such disclosure is required by 
[CONTACT_784]. In any event, pe rsons to whom the information is disclosed must 
be informed that the information is privileged or confidential and may not  be further disclosed by 
[CONTACT_476]. These restrictions on the disclosure shall apply equally to all future information supplied to 
you, whi ch is indicated as privileged or confidential.  
  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 2 
 
 
PROTOCOL APPROVAL  
 
Evaluati ng the Safety and Effectiveness of the Omnipod 
Horizon ™ Automated Glucose Control  System in Patients with 
Type 1 Diabetes  
 
IDE G190270  
Version 5.0 
November 1 2, 2020 
 
 
 
____________________________________ __ 
Trang Ly MBBS FRACP PhD  - SVP, Clinical  and  
Medical Director, Insulet Corporation  
  
 
 
        _____________________  
        Date  
 
 
______________________________________  
Bonnie Dumais, RN – Senior  Director , Clinical Affairs , 
Insulet Corporation   
 
 
        _____________________  
        Date  
 
 
 
____________________________________ __ 
Julie Perkins - Senior Director, Quality and Regulatory,  
Insulet Corporation  
  
 
 
        _____________________  
        Date  
  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 3 
INVESTIGATOR STATEMENT  
 
Evaluating the Safety and Effectiveness of the Omnipod 
Horizon ™ Automated Glucose Control  System in Patients with 
Type [ADDRESS_48424] (IRB) or Food and Drug Administration (FDA). Modifications 
to the study protocol are acceptable only in the form of a protocol amendment, except 
when necessary to protect the safety, rights, or welfare of subjects. I agree to await 
Institutional Review Board (IRB) and Insulet approval for the protocol, informed consent 
and documentation to be presented to subjects before initiating the study pursuant to [ADDRESS_48425] 
complaints for any of the devices utilized in this protocol, and to maintain study related 
documentation (regulatory documentation) for the perio d of time required.  I agree to 
supervise all utilization of investigational study devices and  to ensure their usage is only 
in connection with the Study . I agree to provide a Financial Disclosure Statement to 
Sponsor and will also notify Sponsor if my disclosed financial information changes 
during the Study and up to one year following the closure  of the Study. I have read and 
understand the contents of this protocol. I agree to follow and abide by [CONTACT_45906].  
I understand the information in this document contains trade secrets and commercial 
information that are pr ivileged or confidential and may not be disclosed unless such 
disclosure is required by [CONTACT_784]. In any event, persons whom the 
information is disclosed must be informed that the information is privileged or 
confidential and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure 
will apply equally to all future information supplied to me, which is indicated as 
privileged or confidential.  
_________________________________ __  
Clinical Site Investigator Name  (print)   
_________________________________ __   __________________  
Clinical Site Investigator Signature      [CONTACT_45981]™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 4 
PRINCIPAL CONTACTS  
 
Sponsor Contacts:   Trang Ly, MBBS FRACP PhD  
SVP, Clinical and Medical Director  
Insulet Corporation  
100 Nagog Park  
Acton , MA [ZIP_CODE] 
Office: [PHONE_826] 
E-mail: [EMAIL_864]  
 
Julie Perkins  
Senior Director , Quality and Regulatory  
Insulet Corporation  
100 Nagog Park  
Acton , MA [ZIP_CODE] 
Office: [PHONE_827]  
E-mail: [EMAIL_865]   
 
Protocol Chairs :  Bruce Buckingham , MD  
    Professor, Pediatrics  
Division of Endocrinology and Diabetes  
 Stanford School of Medicine  
    [ADDRESS_48426]  
Palo Alto, CA [ZIP_CODE]  
 E-mail: [EMAIL_866]   
 
Sue Brown, MD  
Associate Professor of Medicine  
Division of Endocrinology  
University of V irginia  
Centers for Diabetes Technology  
[ADDRESS_48427] Floor  
Charlottesville, VA  [ZIP_CODE]  
Email: [EMAIL_867]  
 
 
 
 
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 5 
TABLE OF CONTENTS  
TITLE PAGE ......................................................….......... ........................... ..................... .............. 1 
PROTOCOL APPROVAL  ................................ ................................ ................................ ...............  2 
INVESTIGATOR STATEMENT  ................................ ................................ ................................ ...... 3 
PRINCIPAL CO NTACTS  ................................ ................................ ................................ ................  4 
TABLE OF CONTENTS  ................................ ................................ ................................ .................  5 
PROTOCOL SUMMARY  ................................ ................................ ................................ ................  8 
GLOSSARY OF ACRONYMS  ................................ ................................ ................................ ...... 13 
1 INTRODUCTION  ................................ ................................ ................................ .................  15 
2 OMNIPOD HORIZON™ SYSTEM STUDY DEVICE OVERVIEW  ................................ ...... 16 
2.1 Device Description of the Omnipod Horizon™ System  ................................ . 16 
3 HORIZON ™ DATA PORTAL  ................................ ................................ ...............................  [ADDRESS_48428] THERAPY - PHASE 1  ................................ ................................ .....................  34 
8.1 Visit 2  ................................ ................................ ................................ ............  36 
8.2 Visit 3  ................................ ................................ ................................ ............  37 
9 HYBRID CLOSED -LOOP - PHASE 2  ................................ ................................ ..................  38 
9.1 Challenge Visits  ................................ ................................ ............................  39 
9.2 Visit 4  ................................ ................................ ................................ ............  41 
9.3 Visit 5  ................................ ................................ ................................ ............  42 
9.4 Visit 6  ................................ ................................ ................................ ............  43 
9.5 Visit 7  ................................ ................................ ................................ ............  43 
9.6 Visit 8  ................................ ................................ ................................ ............  43 
9.7 Visit 9  ................................ ................................ ................................ ............  43 
9.8 Visits 10, 11 and 12  ................................ ................................ ......................  44 
9.9 Visit 13 (End of Phase 2)  ................................ ................................ ..............  44 
9.10  Unscheduled Visits (Phase 2)  ................................ ................................ ....... 45 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 6 
9.11  Recommencing After a Pause  ................................ ................................ ...... 46 
9.12  Early Withdrawal (Phase 2)  ................................ ................................ ...........  47 
10 HYBRID CLOSED -LOOP – PHASE 3  ................................ ................................ .................  48 
10.1  Visit 14  ................................ ................................ ................................ ..........  49 
10.2  Visit 15  ................................ ................................ ................................ ..........  49 
10.3  Visit 16  ................................ ................................ ................................ ..........  49 
10.4  Visits 17 and 18  ................................ ................................ ............................  50 
10.5  Visit 1 9 ................................ ................................ ................................ ..........  50 
10.6  Visit 20  ................................ ................................ ................................ ..........  50 
10.7  Visit 21  ................................ ................................ ................................ ..........  50 
10.8  Visit 22  ................................ ................................ ................................ ..........  51 
10.9  Visits 23 (end of study)  ................................ ................................ .................  51 
10.10  Unscheduled Visits (Phase 3)  ................................ ................................ ... 51 
10.11  Early Withdrawal (Phase 3)  ................................ ................................ ....... [ADDRESS_48429] to Follow -up ................................ ................................ .......................  52 
11 SPONSOR  REPRESENTATIVES  ................................ ................................ .......................  52 
12 SAFETY  ................................ ................................ ................................ ...............................  53 
12.1  Types of Known Risks and Benefits  ................................ ..............................  53 
12.2  Hypoglycemia/Hyperglycemia  ................................ ................................ ....... 54 
12.3  Adverse Events  ................................ ................................ .............................  54 
12.3.1  Definitions  ................................ ................................ .............................  54 
12.3.2  Reportable Adverse Events  ................................ ................................ ... 56 
12.3.3  Hypoglycemic Events  ................................ ................................ ............  57 
12.3.4  Hyperglycemic/Ketotic Events  ................................ ...............................  57 
12.3.5  Relationship of Adverse Event to Investigational Device  .......................  58 
12.3.6  Severity (Intensity) of Adverse Events  ................................ ...................  [ADDRESS_48430] (DSMB) ................................ ..........................  [ADDRESS_48431] 6 Weeks of Continuous Phase 2 
Participation Compared to Baseline  ................................ ................................ ...... 69 
13.3.2  Primary Endpoint of Percentage of Time in Range 70 -180 mg/dL During 
Phase 2 of Hybrid Closed -Loop Compared to Phase 1  ................................ .........  69 
13.4  Analysis Sets  ................................ ................................ ................................  70 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 7 
13.4.1  ITT (Intention to Treat) Analysis Set  ................................ ......................  70 
13.4.2  mITT (modified Intention to Treat) Analysis Set  ................................ ..... 70 
13.4.3  PP (Per -Protocol) Analysis Set  ................................ ..............................  70 
13.5  Analysis of Primary and Secondary Endpoints  ................................ ..............  70 
13.5.1  Time in Range Endpoints  ................................ ................................ ...... 71 
13.6  Additional Data Analyses  ................................ ................................ ..............  71 
13.7  Safety Analyses  ................................ ................................ ............................  72 
13.7.1  Evaluation of Adverse Events  ................................ ................................  72 
13.7.2  Evaluation of Device Deficiencies  ................................ .........................  72 
13.8  Baseline Characteristics  ................................ ................................ ...............  72 
13.9  General Statistical Methods  ................................ ................................ ..........  72 
13.10  Missing Data  ................................ ................................ .............................  73 
13.11  Statistical Software  ................................ ................................ ...................  73 
14 DATA HANDLING AND QUALITY ASSURANCE  ................................ ...............................  73 
14.1  Electronic Case Report Forms (eCRFs)  ................................ ........................  [ADDRESS_48432] (IRB)  ................................ ................................ ... 75 
15.4  Informed Consent  ................................ ................................ .........................  76 
15.5  Confi dentiality  ................................ ................................ ...............................  76 
15.6  Modification of the Protocol  ................................ ................................ ...........  77 
15.7  Protocol Deviations  ................................ ................................ .......................  77 
15.8  Study Reporting Requirements  ................................ ................................ ..... 78 
15.9  Selection of Investigators  ................................ ................................ ..............  78 
15.9.1  Financial Disclosure  ................................ ................................ ..............  78 
15.9.2  Investigator Documentation  ................................ ................................ ... 78 
15.10  Clinical Site Training  ................................ ................................ .................  79 
15.11  Device Use  ................................ ................................ ...............................  79 
15.12  Device Returns  ................................ ................................ .........................  79 
15.13  Policy for Publicat ion and Presentation of Data  ................................ .........  79 
15.14  Sponsor or Regulatory Agency Termination of the Study  ..........................  80 
REFERENCES  ................................ ................................ ................................ .............................  81 
APPENDIX A  ................................ ................................ ................................ ................................  84 
  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 8 
PROTOCOL SUMMARY  
Protocol title Evaluati ng the safety and ef fectiveness  of the Omnipod Horizon ™ Automated 
Glucose Control  System in patients with type 1 diabetes  
Protocol ID  G190270  
Purpose  To evaluate the safety and effectiveness  of the Omnipod Horizon ™ Automated 
Glucose Control  System in patients with type [ADDRESS_48433] of three  phases:  
 
1) 14-day standard therapy outpatient phase (Phase 1)  
2) 13-week  outpatient hybrid closed -loop phase  (Phase 2)  
• Phase 2 excludes periods due to a study pause  
3) 12-month hybrid -closed -loop extension phase (Phase 3)  
 
Subjects will be enrolled across 12-20 clinical study sites. The 2 00 evaluable  
subjects will be comprised of two age cohorts of 1 00 subjects each as follows:  
 
• 100 subjects aged 6 -13.9 years  
• 100 subjects aged 1 4-70 years  
Indication  The Omnipod Horizon ™ Automated Glucose Control  System is a single 
hormone insulin delivery system intended for the management of diabetes in 
persons requiring insulin.  Continuous subcutaneous insulin infusion may be 
delivered by [CONTACT_45907] -defined settings (manual mode) or automatically adjusted in 
response  to feedback from a continuous glucose monitor (CGM).  
 
The Omnipod Horizon ™ System can automatically increase insulin  delivery  
based on CGM sensor glucose values and can decrease or suspend delivery of 
insulin when the glucose value falls below or is pred icted to fall below 
predefined threshold values. The Omnipod HORIZON™ System is 
interoperable with compatible iCGMs  and ACE pumps . 
 
The Omnipod Horizon ™ System is designed to assist patients with diabetes in 
achieving glycemic targets set by [CONTACT_45908] c are providers.  
Study duration  The study is expected to be completed within 30-months which includes clinical 
site initiation to completion of Phase 3 and all data entry and monitoring 
procedures. The sponsor intends to submit results from Phase 2 for marketing 
clearance after data collection for Phase 2 is complete.  The results from Phase 
3 will be submitted separately.   
Investigational 
device s The O mnipod Horizon ™ Automated Glucose Control  System is comprised of 
the following components:  
• Omnipod Horizon ™ tubeless, insulin delivery  alternate controller enabled 
(ACE) pump (Pod)  with the Horizon™ algorithm  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 9 
• Omnipod Horizon ™ Personal Diabetes Manager (PDM ) which is a 
Samsung J3 locked down Android  device that operates  the Omnipod 
Horizon ™ App.  
• Dexcom G6 - Continuous Glucose Monitoring (CGM) system  
Non-
investigational, 
commercially 
available devices  • Contour® Next One blood glucose meter (Ascensia Diabetes Care, [ADDRESS_48434], Parsippany, NJ [ZIP_CODE] [LOCATION_003])  
• Precision Xtra ketone meter (Abbott Diabetes Care Inc., [ADDRESS_48435], Alameda, CA [ZIP_CODE] [LOCATION_003])  
Primary safety 
objective  To evaluate the safety of the Omnipod Horizon ™ Automated Glucose Control  
System in patients with type 1 diabetes    
Primary safety 
endpoints  The primary safety objective will be evaluated by [CONTACT_45909] 2 , and separately during Phase 3 :  
 
• Incidence rate of severe hypoglycemia (events per person months)  
• Incidence rate of diabetic ketoacidosis (DKA) (events per person months)   
Primary 
effectiveness  
objective  To evaluate the effectiveness  of the Omnipod Horizon ™ Automated Glucose  
Control  System.  
Primary 
effectivenes s 
endpoint s • A1C after at least 6 weeks of continuous Phase 2 participation c ompared to 
baseline  
• A1C at Visit 16 , 19, 21, and 23  compared to baseline  
• Percentage of time in range (70-180 mg/dL ) during Phase 2 and separately 
during Phase 3 of the hybrid closed -loop phase compared to Phase 1 
(standard therapy)  
Secondary 
objective  To evaluate additional glycemic measures of effectiveness of the Omnipod 
Horizon™ Automated Glucose Control System   
Secondary 
endpoints  The secondary objective will be evaluated  using the following per subject 
endpoints  with prespecified hypotheses : 
 
• Glucose metrics from system CGM during the hybrid closed -loop phase 
for Phase 2 will be compared to Phase 1 overall:  
• % of time  > 180 mg/dL  
• % of time  < 70 mg/dL  
 
Additional per subject secondary endpoints without  prespecified hypotheses 
used to evaluate the secondary objective include:  
 
• A1C:  
• A1C after at least 8 weeks of continuous Phase 2 participation at 
the end of Phase 2 (Visit 13), at 6 months (Visit 16 ), and at the end 
of Phase 3 (Visit 23 ; approximately 15 months ) 
• Change from baseline in A1C after at least [ADDRESS_48436] 8 weeks of continuous Phase 2 
participation at the end of Phase 2 (Visit 13), at 6 months (Visi t 16), 
and at the end of Phase 3 (Visit 23 ; approximately 15 months )  
• Proportion of subjects demonstrating an improvement from 
baseline in A1C after at least [ADDRESS_48437] 8 weeks of continuous Phase 2 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 10 
participation at the end of Phase 2 (Visit 13), at 6 months (Visit 16) , 
and at the end of Phase 3 (Visit 23 ; approximately 15 months ) 
 
• Glucose metrics from system CGM during the hybrid closed -loop phase 
during  Phase 2 , and separately during  Phase 3 , will be compared to 
Phase 1 during the day, overnight and overall:  
 
• Mean glucose  
• % of time in range 70 -180 mg/dL  
• % of time in range  70-140 mg/dL  
• % of time  > 180 mg/dL  
• % of time  ≥ 250 mg/dL  
• % of time ≥ 300 mg/dL  
• % of time  < 70 mg/dL  
• % of time  < 54 mg/dL  
• Standard deviation  
• Coefficient of variation  
 
• Percentage of time in hybrid closed -loop as proportion of overall device 
usage time during Phase 2 , and separately during  Phase 3  
• Glucose management indicator (GMI) based on overall mean glucose 
during Phase 2 , and separately during  Phase 3  will be compared to 
Phase 1  
• Insulin requirements during Phase 2 , and separately during Phase 3  
will be compared to Phase 1:  
 
• Total daily i nsulin  (TDI)  (units, units/kg)  
• Total daily basal insulin (units, units/kg)  
• Total daily bolus insulin (units, units/kg)  
 
• Change from baseline in BMI (kg/m2) at end of Phase [ADDRESS_48438] meet all of the following criteria to be included in the study:  
1. Age at time of consent /assent  6-70 years  
2. Subjects aged < [ADDRESS_48439] be living with parent/legal guardian  
3. Diagnosed with type [ADDRESS_48440] 6 months. Diagnosis is based on 
investigator’s clinical judgment  
4. Deemed appropriate for pump therapy per investigator’s assessment ta king 
into account previous history of severe hypoglycemic and hyperglycemic 
events, and other comorbidities  
5. Investigator has confidence that the subject can successfully operate all 
study devices and is capable of adhering to the protocol  
6. Willing to use only the following types of insulin during the study:  Humalog, 
Novolog, Admelog  or Api[INVESTIGATOR_45861]   
7. Must be willing to travel to and participate in meal and exercise 
challenges during 5 -days of the hybrid closed -loop phase  
8. Willing to wear the syste m continuously throughout the study  
9. A1C <10% at screening visit  
10. Must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 11 
the sole source of Dexcom data (with the exception of the Dexcom Follow 
App) during the hybrid closed -loop phase  
11. Subjects scoring ≥ [ADDRESS_48441] and  who can be available overnight  
12. Able to read and speak English fluently  
13. Willing and able to sign the Informed Consent Form (ICF) and/or has a 
parent/guardian willing and able to sign the ICF. Assent will be obtained 
from pediatric and adolescent subjects  aged < 18 years  per State 
requirements.  
 
Exclusion Criteria  
Subjects who meet any  of the following criteria will be excluded from the study:  
1. A medical condition, which in the opi[INVESTIGATOR_871], would put the 
subject at an unacceptable safety risk 
2. History of severe hypoglycemia in the past [ADDRESS_48442] 6 months, unrelated to an intercurrent illness, 
infusion set failure or initial diagnosis  
4. Diagnosed with sickle cell disease  
5. Diagnosed with hemophilia or any other bleeding disorders  
6. Plans to receive blood transfusion over the course of the study  
7. Currently diagnosed with anorexia nervosa or bulimia  
8. Acute or chronic kidney disease (e.g. estimated GFR < 45)  or currently on 
hemodialysis  
9. History of adrenal insufficiency  
10. Has taken oral or injectable steroids within the past 8 -weeks or plans to 
take oral or injectable steroids during the course of the study  
11. Unable to tolerate adhesive tape or has any unresolved skin condition in the 
area of sensor or pump placement  
12. Plans to use insulin other than U -100 insulin intended for use in the study 
device during the c ourse of the study  
13. Use of non-insulin anti -diabetic medication other than metformin  (e.g. GLP1 
agonist, SGLT2 inhibitor, DPP -4 inhibitor, pramlintide)  
14. Current or known history of coronary artery disease that is not stable with 
medical management, including unstable angina, or angina that prevents 
moderate exercise despi[INVESTIGATOR_45862], or a history of myocardial 
infarction, percutaneous coronary intervention, or coronary artery by[CONTACT_45910] 12 -months.  
15. For subjects >50 years old or with diabetes duration >20 years , abnormal 
electrocardiogram consistent with increased risk of arrhythmia, ischemia, or 
prolonged QT c interval (> 4 50 ms)  
16. Thyroid Stimulating Hormone (TSH) is outside of normal range with 
clinical s igns of hypothyroidism or hyperthyroidism  
17. Pregnant or lactating, or is a woman of childbearing potential and not on 
acceptable form of birth control (acceptable includes abstinence, condoms, 
oral/injectable contraceptives, IUD or implant)  
18. Participation in another clinical study using an investigational drug or device 
other than the Omnipod Horizon™ Automated Glucose Control  System  
within the preceding 30 -days or intends to participate during the study 
period   
19. Unable to follow clinical protocol for the duration of the study or is otherwise 
deemed unacceptable to participate in the study per the investigator’s 
clinical judgment  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 12 
Study schedule 
overview  The study schedule consists of the following three  phases:  
 
1) 14-day outpatient standard therapy phase  (Phase 1)  
2) 13-week outpatient hybrid closed -loop phase  (Phase 2)  
o A subset of  subjects will participate in 5-days of supervised 
challenge s 
o Phase 2 excludes periods due to a study pause  
3) 12-month hybrid closed -loop extension phase (Phase 3)  
 
Following subject screening, enrollment, and device  training, subjects will 
commence the outpatient standard therapy phase  of the study .  
 
Current Dexcom G6 CGM users may provide data from a [ADDRESS_48443] therapy phase, subjects will be trained on the 
system and  transition to the hybrid closed -loop phase initiat ing treatment with 
the Omnipod Horizon ™ System . Subjects in each cohort will participate in 
prescribed challenges during any consecutive 5 -day period  during Phase 2 of 
the hybrid closed -loop phase. Subjects  who complete Phase 2 can commence 
their participation in the extension phase  (Phase 3).  
 
Note: Subjects having completed the prepi[INVESTIGATOR_45863] 5 of Phase 2 ( hybrid closed -loop) since Phase 1 
(standar d therapy ) was completed as part of the prepi[INVESTIGATOR_45864].   
 
  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48444]  
ITT Intention to Treat  
MD Doctor of Medicine  
MDI Multiple Daily Injections  
mg Milligram  
mITT  Modified Intention to Treat  
mmol  Millimole  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48445]  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48446] significant barrier to improved 
glucose control in patients with diabetes.3 A paper by [CONTACT_45911] . al. reported on data 
collected by [CONTACT_941] T1D Exc hange and found an annual incidence of 11.8% of one or more 
severe hypoglycemic events defined as a seizure or loss of consciousness. The annual 
incidence of severe hypoglycemic events increased to 18.6% in patients with diabetes 
duration greater than [ADDRESS_48447] of acute and chronic complications 
on the longevity of patients with diabetes. Livingstone et . al. found premature death in a 
Scottish registry of patients with diabetes of 11 years in males and 13 years in females.5 
Lind et . al. found a twofold increase in mortality in a Swedish registry compared with 
age-matched non -diabetic cohorts even in patients with recommended levels of 
glycemic control ( A1C < 7.0%).[ADDRESS_48448] recent treatment guidelines from the 
American Diabetes Association now recommend that adults with type 1 diabetes should 
aim for target A1C levels of 7.0% and that children and adolescents should aim for 
target A1C levels of 7.5%.7 These recommendations are equivalent to a mean blood 
glucose of 154 mg/dL in adults and 169 mg/dL in children and adolescents compared 
with mean blood glucose in patients without diabetes of 100 mg/dL or less.[ADDRESS_48449] notably the advent of faster analog insulins, the widespread use of insulin pumps 
and the introduction of continuous glucose monitoring systems. Despi[INVESTIGATOR_45865], diabetes data registries continue to show that the majority of patients are 
unable to meet recommended glycemic targets with available medication and 
technology. In the 2012  report from the T1D  Exchange  Registry , Beck et . al. found the 
average A1C across all ages greater than 8.0% or, equivalently, greater than 183 
mg/dL and only 30% of patients met the ADA target A1C of 7.0% (adults) and 7.5% 
(children).9 A more recent paper from the T1D Exchange Registry by [CONTACT_45912]. al. 
comparing  the 2016 -2018 cohort with 2010 -2012 cohort indicated that among the 9,657 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48450] 3 years of diabetes duration in 
2010 -2012, mean HbA1c was higher in the 2016 -2018 cohort . The increase in HbA1c 
over time was predominately seen in adolescents and young adults . The American 
Diabetes Association  (ADA) HbA1c target as of 2018 of < 7.5% for children and 
adolescents was achieved by [INVESTIGATOR_13701] a small percentage of youth < 18 years of age (17%); 
only 21% of adults achieved the ADA treatment goal of < 7.0%.10 
The current dilemma of persistent poor diabetes outcomes despi[INVESTIGATOR_45866], insulin 
pumps and continuous glucose monitoring systems is summarized in the FDA 
Guidance Document on Artificial Pancreas Device Systems: “Even with the aid of these 
devices, maintaining blood glucose concentrations within a suggested optimal range is 
a daily struggle for people living with diabetes mel litus and the risk of hypoglycemia 
associated with attempts at improved glycemic control remains an ever -present 
danger”.11 
Insulet has developed the Omnipod Horizon ™ Automated Glucose Control  System  
(hereafter named  Omnipod Horizon ™ System or Omnipod Horizon ™) which is s imilar 
in function to the systems described in the FDA guidance document dated November 9, 
[ADDRESS_48451] 
of an Omnipod® tubeless , insulin delivery  ACE pump, a Personal Diabetes Manager 
(PDM), and the Dexcom  G6 CGM . The control algorithm will reside  on the Pod.  
This pi[INVESTIGATOR_45867] ™ System . Maximum stressors  to the system , by [CONTACT_45913] , will be assessed during [ADDRESS_48452] of  prolonged periods 
of moderate to high intensity exercise  as well as me al challenges . Challenges will be 
conducted in an environment closely monitored by [CONTACT_45914].  
 
2 OMNIPOD HORIZON™ SYSTEM STUDY DEVICE OVERVIEW  
This study will evaluate the safety and effectiveness of the Omnipod Horizon ™ System . 
The Omnipod Horizon™ System is a hybrid closed -loop automated insulin delivery  
(AID) system  developed by [CONTACT_45915] . 
2.1 Device Description of the Omnipod Horizon ™ System  
The Omnipod Horizon™ System intended for commercialization is composed of three 
primary components  as shown in Figure  1: 
 
• Omnipod Horizon™ Controller – Horizon App (PDM) and Algorithm  
• Omnipod Horizon™ ACE Pump  – Pod  
• iCGM  – Dexcom G6  
The Omnipod Horizon ™ System will provide automated insulin delivery when 
connected to CGM . The system is expected to reduce hypoglycemia without incurring 
an unacceptable inc rease in hyperglycemia and mean glucose. The system is also 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48453]-prandial control requires the user to deliver  meal boluses as in current 
open -loop therapy, but the  normal operation of the control algorithm will be expected to 
compensate for mismatched  meal boluses and prevent prolonged hyperglycemia. The 
system uses a control -to-target strategy that attempts to achieve and maintain a set 
target glucose level.  
Figure  1:  System components  of the Omnipod Horizon™ System   
2.1.1. Omnipod Horizon™ Controller ( App and Algorithm ) 
 
The Omnipod Horizon ™ Controller is composed of two parts: the Horizon app lication 
(“app”)  and the model predictive control (MPC) algorithm  on the Pod. The MPC 
algorithm provides insulin micro -boluses once every [ADDRESS_48454] -prandial control will  
require the user to give meal bolu ses in the same manner as current pump therapy, but 
normal  operation of the MPC algorithm will compensate for missed meal boluses and 
mitigate prolonged hyperglycemia. The MPC algorithm uses a control -to-target strategy 
that attempts to achieve and maintai n a set target glucose value , thereby [CONTACT_45916] . The MPC algorithm  resides on 
the Pod (Pump) component of the Omnipod Horizon™  System ( similar to the DASH 
ACE pump cleared in  K191679 ), as described further below ). 
 
The Omnipod Horizon ™ app will be the primary user interface and will be used to start 
and stop a Pod, program basal and bolus calculator settings for Manual Mode  as well 
as program settings specific for Automated Mode  (hybrid clo sed-loop).  
 
 
Manual Mode  
 
In Manual Mode , the Horizon ™ System will function equivalently to the Omnipod® 
DASH System,  which was first cleared under K180045 , most recently under K191679 . 

   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 18 
This includes  delivering insulin at programmed basal rate s and bolus amounts  with the 
option to set temporary basal profiles. The Omnipod  Horizon ™ Controller will also have 
the ability to function as a sensor augmented pump in Manual Mode , using sensor 
glucose data provided by [CONTACT_45917] . 
 
Automated Mode  
 
In Automated Mode , the system will support the use of multiple target glucose values , 
currently intended  to be 110 -150 mg/dL at commercialization , in 10 mg/dL increments. 
The experience for the user will  reflect current setup flows where by [CONTACT_45918], glucose  targets and bolus calculator 
settings. These in turn will inform the MPC algorithm for insulin dosing  parameters. The 
insulin dosing parameters will be adapted over time based on the total daily insulin 
(TDI)  delivered  during each Pod use. A temporary hypoglycemia protection mode ( Hypo 
Protect) may be implemented by [CONTACT_45919] . With Hypo Protect, t he algorithm reduces insulin  delivery and is intended for use 
over temporary durations when insulin  sensitivity is expected to be higher , such as 
during exercise.  
 
The Omnipod Horizon ™ System will include two apps  on a locked -down smartphone 
(the Samsung J3), referred to as  Personal D iabetes Manager ( PDM): the Horizon App 
and the Dexcom App. The Horizon  App, which will have a similar interface to the 
cleared Omnipod® DASH System (K1 [ZIP_CODE] ), will allow the  use of large text, graphics, 
and on-screen  instructions to prompt the user through  set-up processes. It  will also be 
used to program the user’s custom  basal insulin delivery profile, check the Pod status, 
initiate bolus doses of insulin, make changes to a  patient’s insulin delivery profile, 
handle system alerts and alarms, and enter Automated Mode .  
 
The Dexcom App  interface is identical to the current app of the interoperable Dexcom 
G6 Continuous Glucose Monitoring  System ( K191450 ) and will provide CGM data, 
alerts, and alarms to the user.  
 
The Horizon App and  Dexcom App will not direc tly communicate  with one another . 
Instead,  the iCGM transmitter will communicate EGV (estimated glucose values)  
directly to the Pod . The Dexcom  transmitter number must be  entered into the Horizon 
App, and th is information is  sent to the Pod  to allow transmission of EGV . The Pod will 
pair directly to the transmitter to receive  EGV  for the algorithm and  also send s the EGV  
back to the  Horizon A pp as shown in Figure  1. 
 
The Omnipod Horizon ™ Controller provides the ability to calculate a suggested bolus 
dose through the use  of the bolus calculator. The bolus  calculator will have the option 
for user selected population of the EGV , which is commun icated to the app via the  Pod. 
This suggested bolus calculation feature is provided as a convenience to the user to aid  
in determining the suggested bolus dose based on ingested carbohydrates, most recent 
sensor  glucose reading  (or blood glucose reading if  using fingerstick) , programmable 
correction factor, insulin to carbohydrate ratio, target glucose value and insulin on  board 
(IOB) . IOB is calculated by [CONTACT_45920].  
 
As with the cleared Omnipod® DASH System, Insulet will utilize a proprietary encrypted 
security stack  embedded within the Bluetooth Low Energy ( BLE) communication 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 19 
between the Horizon app and Pod. The communication to the  iCGM will use Dexcom’s 
communication p rotocol. The proprietary security stack increases the resilience  of the 
device and improves the ability of the system to be protected in the event of future 
identification of  vulnerabilities in standard communication protocols.  
 
2.1.2. Omnipod Horizon ™ ACE  Pump  
The Pod component of the Omnipod Horizon™  System  is similar to the Omnipod® 
DASH ACE Pump cleared under K191679.   Compared to the DASH ACE Pump 
(K191679), t he Horizon ™ ACE Pump (Pod) has additional software to optimize 
communication to accept inputs from the iCGM ( initially the Dexcom G6) and the 
Horizon ™ Controller .  The insulin delivery mechanism and the patient and fluid 
contact[CONTACT_45921].  
 
The Pod is a lightweight, self -adhesive device that the user fills with U -100 rapid -acting 
insulin and wears  directly on their body. The Pod delivers insulin into the user’s body 
through a small flexible tube, called a  cannula, based on the commands from the 
compatible controller. In the Omnipod Horizon ™ System,  the Pod will house the MPC 
algorithm and communicate directly with the iCGM  and the Horizon App . The algorithm 
commands  the Pod’s insulin delivery in the form of  micro -boluses based on predicted 
glucose values. As with the  cleared Omnipod® DASH System, the Pod of the Omnipod 
Horizon ™ System will come pre -packaged in a  sterile container with a fill needle and  a 
fill syringe. Figure 2 below is a representation of the  Pod.  
 
 
Figure 2:  The Pod of the Omnipod Horizon ™ ACE pump  
 
 
2.1.3. iCGM  
The third component of the Omnipod Horizon™ System is the iCGM . The Omnipod 
Horizon™ System will be interoperable with a compatible iCGM, currently the Dexcom 
G6 Continuous Glucose Monitoring System ( K191450 ). The Omnipod Horizon ™ Pod  
will communicate with the Dexcom G6 via Bluetooth Low Energy ( BLE). Glucose values 

   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 20 
from the Dexcom transmitter will be sent to the MPC algorithm residing on the Pod and 
used in insulin dosing adjustments. The glucose values from the Dexcom transmitter 
will be sent independently to the Dexcom App on the controller .  
3 HORI ZON ™ DATA PORTAL  
Data are securely uploaded from the PDM to Insulet Cloud by [CONTACT_45922].  Data 
are then transferred from Insulet Cloud to the Horizon Data Portal (HDP), which is a 
platform for data review and management. The HDP runs on an Amazon -based web 
server . The HDP will provide insights including but not limited to:  time in range, time at 
each  target BG , automated/manual mode comparisons, and time spent in each mode . 
 
Investigators will have access to all uploaded data and be able to v iew historical trends.  
The HDP will function as the  data management review platform for this study .  
 
4 RESULTS FROM FEASIBILITY STUDIES  
The Omnipod Horizon ™ System has been tested in [ADDRESS_48455] also been published in Diabetes Technology and Therapeutics 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23, 29. 
5 STUDY SUMMARY  
5.1 Study Purpose  
The purpose of this study is to assess the safety and effectiveness  of the 
Omnipod Horizon ™ System in patients  with type 1 diabetes .     
5.2 Study Design  
This is a  single-arm, multi -center, prospective clinical study . A total of up to 240 
subjects aged 6 -70 years with type 1 diabetes will be enrolled in the study in order 
to obtain a minimum of 200 evaluable subjects , 100  evaluable subjects in each 
age cohort ( Table 1:  Cohorts ). Subject s will be considered evaluable if they have 
at least [ADDRESS_48456] identification number .  
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 21 
The study schedule consists of the following three  phases:  
1) 14-day outpatient  standard therapy phase  (Phase 1)  
2) 13-week outpatient hybrid closed -loop phase  (Phase 2)  
▪ A subset of subjects will participate in 5-days of supervised  challenge s 
▪ Phase 2 excludes periods due to a study pause  
3) 12-month hybrid closed -loop extension phase  (Phase 3)  
 
Note: Subjects having completed the prepi[INVESTIGATOR_45868] 2 since Phase 1 was completed as part of the prepi[INVESTIGATOR_45869].     
 
Figure 2:  Study Schedule Timeline  
 
 
14-Days  
Standard  
Therapy   
13-Weeks  
Hybrid Closed -loop 12-Month Extension  
 
 
 
Cohorts are defined as  shown in Table 1: 
Table 1:  Cohorts  
Cohort (Name)  Age Range  N (minimum  evaluable 
for primary endpoint ) 
Adults  14-[ADDRESS_48457] glucose measurements over 14 -days while s ubjects manage their 
diabetes at home per their usual routine while wearing a study CGM while remaining on 
their current MDI or pump therapy , and sensor, if applicable,  for 14 -days.   
After completion of Phase 1 ( the standard therapy phase ), subjects will be trained on 
the system and transition to  Phase 2 (13 -week  hybrid closed -loop phase ) initiat ing 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 22 
treatment with the Omnipod Horizon ™ System .  Subjects in each cohort will participate 
in prescribed challenges during any consecutive 5-days of the 13-week hybrid closed -
loop phase . Phase 2 will be followed by  a 12-month hybrid closed -loop phase (Phase 
3). 
Tables 2  and 4 outline  the schedule of assessments  for each phase of the study.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 23 
Table 2:  Schedule of Assessments  for Phase 1  and Phase 2  
Assessment Schedule  Screening  ST1 ST2 Hybrid Closed -Loop (HCL)  EWa 
  Phase 1e Phase 2c   
Visit Number  1 2 3 4 5 e 6 7 8 9 10 11 12 13 UVb   
Study Day/Visit Windowl -30 to -14d  
HCL start  -14d to 
HCL 
start  -1d to 
HCL 
start  1 2 
±1d 3 
±1d 10 
±3d 24 
±3d 38 
±3d 52 
±3d 66 
±3d 80 
±3d 94 
±3d N/A   
Telephone (T) or Office (O) Visit  O O O O T/O T/Of T/Of T/Of T/Of T/Of T/Of T/Of T/Of T/Of O 
Labo ratory Assessments  
A1c X                       X   X 
TSH X                             
Creatinine Level  X                             
Pregnancy Test  X     X     X   X        X     
Clinical Assessments  
Informed Consent  X      Xg                      
Medical History (including 
demographics)  X                             
Confirm Eligibility  X      Xg                      
Concomitant medications  X Xh   Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh 
Average total daily insulin (~ 7 
days)   X   X                       
Average total basal insulin (~ 7 
days)   X   X                       
Average total bolus insulin (~ 7 
days)   X   X                       
Pump settings/MDI dosing    X   X                       
Height  X                      X   X 
Weight  X                      X   X 
Vital signs  X          X   X       X  X 
Electrocardiogramd (if 
applicable)  X                             
Adverse events     X X  X Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 24 
Assessment Schedule  Screening  ST1 ST2 Hybrid Closed -Loop (HCL)  EWa 
  Phase 1e Phase 2c   
Visit Number  1 2 3 4 5 e 6 7 8 9 10 11 12 13 UVb   
Study Day/Visit Windowl -30 to -14d  
HCL start  -14d to 
HCL 
start  -1d to 
HCL 
start  1 2 
±1d 3 
±1d 10 
±3d 24 
±3d 38 
±3d 52 
±3d 66 
±3d 80 
±3d 94 
±3d N/A   
Telephone (T) or Office (O) Visit  O O O O T/O T/Of T/Of T/Of T/Of T/Of T/Of T/Of T/Of T/Of O 
Questionnaires  
See Table 4 for specific 
questionnaires  X X             
      X  X 
Study Devices  
Training on Glucagon 
administration and information 
on treatment of 
hypo/hyperglycemia    X                           
Horizon Data Portal  
initiation/discontinuation     X         X  X 
Study device training    Xi   Xj                       
Dispense/Return  
BG/Ketone meter, and CGM    X                     X   X 
QC testing of BG/Ketone meter 
by [CONTACT_3725]    X                           
CGM sensor placement (as 
needed throughout)    X                           
Assess CGM usage and data 
criteria has been met    Xk  X                         
Dispense/Return Horizon System        X                 X   X 
Complaints/device deficiencies        Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh 
Device uploads         X X X X X X X X X X  X 
Data review     X X X X X X X X X X X X 
 
 
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 25 
 
 
 
Table 3:  Schedule of Assessments for Phase  3 
Assessment Schedule  Hybrid Closed -Loop (HCL)      
Phase 3      
Visit Number  14 15 16 17 18 19 20 21 22 23 UV EW 
Study Day/Visit Window  120 
± 5d  150 
± 5d  180 
± 5d  210 
± 5d  240 
± 5d  270 
± 5d  315 
± 5d  360 
± 5d  405 
± 5d  450 
± 5d      
Telephone (T) or Office (O) 
Visit  T/Of T/Of T/Of T/Of T/Of T/Of T/Of T/Of T/Of O T/Of  O  
Laboratory Assessments  
A1C     X     X  X  X   X 
Pregnancy Test     Xf     Xf          
Clinical A ssessments  
Informed Consent       Xm       
Concomitant Medications  X X X X X X X X X X X X 
Height                X   X 
Weight                X   X 
Adverse Events  X X X X X X X X X X X X 
Study Devi ces 
Return Horizon System                X   X 
Complaints /Device 
Deficiencies  Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh Xh 
Device Uploads (BG/Ketone 
Meter)  Xf Xf Xf Xf Xf Xf Xf Xf Xf X  X 
Data Review  Xn Xn Xn Xn Xn Xn Xn Xn Xn Xn Xn Xn 
 
Abbreviations:  S=Screening; ST1=Standard Therapy Day One; HCL=Hybrid Closed -loop; EW=Early Withdrawal; QC=Quality Control Testing;  UV=Unscheduled 
Visit  
aEarly withdrawal visit will only be conducted for any subjects that started but did not complet e the full study to include standard therapy and the hybrid 
closed -loop phase.   
bUnscheduled visits will serve as extra study visits, if needed.   For unscheduled visits pertaining to a study pause and recommencement, sites should follow the 
assessments as defined in section 9.10 . 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 26 
cChallenges can occur during any consecutive 5 -days during Phase 2 of the hybrid closed -loop phase.  A follow up telephone visit will occur the following day 
after the conclusion of the challenge period.  
dElectrocardiogram required for subjects >50 years o ld or with diabetes duration >20 years  
eSubjects extending into the pi[INVESTIGATOR_45870] 5 of pi[INVESTIGATOR_9205] 2.   
fVisits identified as "T/O" can either be conducted in person at the clinical s ite or over the telephone.  Visits identified as "O" can only be conducted in person at 
the clinical site.   Vital signs, device uploads/data review from the BG and Ketone meter, and pregnancy tests are not required at any visit condu cted via 
telephone.  
gPrepi[INVESTIGATOR_45871].  If original prepi[INVESTIGATOR_45872] [ADDRESS_48458] reconsent prior to co mmencing the extension phase (Phase 3) on or before Visit 13.   
hDocumentation only applicable if there are changes from previous assessment  
iStudy device training for the CGM, blood glucose and ketone meters  
jStudy device training for the Omnipod Horiz on™ System  
kSubjects deemed exempt from wearing the study CGM for 14 -days will be eligible to immediately commence the hybrid closed -loop phase at Visit 4 and may 
skip Visit 3/ST2  (in which case, Visit 1, Visit 2/ST1 and Visit 4 may all occur on the same day)   
lIn the event of overlappi[INVESTIGATOR_45873], no visits occurring during Phase [ADDRESS_48459] 
occur on or any time before commencing that study interval (e.g. consent for first [ADDRESS_48460] occur on or before Visit 19).  
nData review for Horizon Automated  Mode  to occur at all visits 
  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 27 
 
 
Table 4:  Questionnaires  
Visit    Age Groups * 
Adult  
(ages 18 -70) Teen  
(ages 12 -17.9 ) Caregiver  of Teen  
(ages 12 -17.9)  Pediatric  
(ages 6-11.9 ) Caregiver  of Pediatric  
(ages 6 -11.9)  
Screening   Clarke  Clarke  n/a n/a Clarke  
Visit 2 (Phase 1)  WHO -5 
EQ-5D-5L 
T1DDS  
DTSQs  
 
Hypo glycemia  
Conf idence Scale  
HABS  
PSQI  
IDSS (T1)  
SUS WHO -5 
EQ-5D-5L 
 
 
PAID -Teen  
Hypo glycemia  
Conf idence Scale  
 
PSQI  
 
SUS WHO -5 
 
 
DTSQs  
P-PAID -Teen  
Hypo glycemia  
Conf idence Scale  
 
PSQI  
IDSS (T1)   
EQ-5D-Y 
 
 
PAID -Child  WHO -5 
 
 
DTSQ s 
P-PAID -Child  
Hypo glycemia  
Conf idence Scale  
 
PSQI  
IDSS (T1)  
SUS 
End of Phase 2 
(~13 weeks) or 
Early 
Withdrawal  WHO -5 
EQ-5D-5L 
T1DDS  
DTSQc  
 
Hypo glycemia  
Conf idence Scale  
HABS  
PSQI  
IDSS (T1)  
SUS 
INSPI[INVESTIGATOR_21392] -Adult  
Clarke  
Human Factors  WHO -5 
EQ-5D-5L 
 
 
PAID -Teen  
Hypo glycemia  
Conf idence Scale  
 
PSQI  
 
SUS 
INSPI[INVESTIGATOR_21392] -Youth  
Clarke  
Human Factors  WHO -5 
 
 
DTSQc  
P-PAID -Teen  
Hypo glycemia  
Conf idence Scale   
 
PSQI  
IDSS (T1)  
 
INSPI[INVESTIGATOR_21392] -Parent  EQ-5D-Y 
 
 
 
PAID -Child  
 
 
 
 
 
 
INSPI[INVESTIGATOR_21392] -Youth  WHO -5 
 
 
DTSQ c 
P-PAID -Child  
Hypo glycemia  
Conf idence Scale  
 
PSQI  
IDSS (T1)  
SUS 
INSPI[INVESTIGATOR_21392] -Parent  
Clarke  
Human Factors  
*Some questionnaires require completion by [CONTACT_45923].  Caregivers completing questionnaires must be the 
caregiver that provided consent for study participation, or subsequently signed a consent form.   It is preferable that the careg iver 
completing a questionnaire at screening or Visit 2 is the same caregiver completing questionnaires at the End of Phase 2  (~13 weeks  
of hybrid closed -loop participation ) or at the time of withdrawal from the study.  No questionnaires will be completed d uring or at the 
conclusion of Phase 3.   
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 28 
6 OBJECTIVES AND ENDPOINTS  
6.1 Primary Safety Objective  
The primary safety objective of this study is to  evaluate the safety of the Omnipod 
Horizon™ System .  
 
6.1.1  Primary Safety Endpoints  
The primary safety objective will be evaluated by [CONTACT_45909] 2 , and separately during  Phase 3:  
 
• Incidence rate of severe hypoglycemia (events per person months)  
• Incidence rate of diabetic ketoacidosis (DKA) (events per person months)   
6.2 Primary Effectiveness Objective  
The primary effectiveness objective of this study is to evaluate the effectiveness  of 
the Omnipod Horizon ™ System . 
 
6.2.1  Primary Effectiveness Endpoints  
There are two primary effectiveness endpoints.  
 
• A1C after at least  6 weeks of continuous Phase 2 participation  compared 
to baseline  
• A1C at Visit 16 , 19, 21, and 23  compared to baseline  
• Percentage of time in range (70-180 mg/dL ) during Phase 2 and 
separately during Phase 3 of the hybrid closed -loop phase as compared to 
Phase 1 ( standard therapy ) 
6.3 Secondary Objective  
The secondary  objective of this study is to evaluate  additional glycemic measures 
of effectiveness of the Omnipod Horizon™ System .  
6.3.[ADDRESS_48461] 
endpoints  with prespecified hypotheses:   
• Glucose metrics from system CGM  during the hybrid closed -loop phase for 
Phase 2 will be compared to Phase 1  overall : 
• % of time  > 180 mg/dL  
• % of time  < 70 mg/dL  
 
Additional per subject secondary endpoints without  prespecified hypotheses 
used to evaluate the secondary objective include :  
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 29 
• A1C:  
o A1C after at least 8 weeks of continuous Phase 2 participation at 
the end of Phase 2 (Visit 13), at 6 months (Visit 16) , and at the 
end of Phase 3 (Visit 23 ; approximately 15 months ) 
o Change from baseline in A1C after at least [ADDRESS_48462] 8 weeks of continuous Phase 
2 participation  at the end of Phase 2 (Visit 13),  at 6 months (Visit 
16), and at the end of Phase 3 (Visit 23 ; approximately 15 
months )   
o Proportion of subjects demonstrating an improvement from 
baseline in A1C after at least [ADDRESS_48463] 8 weeks of continuous Phase 2 
participation at the end of Phase 2 (Visit 13),  at 6 months (Visit 
16), and  at the end of Phase 3 (Visit 23 ; approximately 15 
months ) 
  
• Glucose metrics from system CGM  during the hybrid closed -loop phase 
during Phase 2 , and separately during  Phase 3 , will be compared to Phase 1  
during the day, overnight, and overall : 
 
• Mean glucose  
• % of time  in range 70 -180 mg/dL  
• % of time  in range 70 -140 mg/dL  
• % of time  > 180 mg/dL  
• % of time  ≥ 250 mg/dL  
• % of time ≥ 300 mg/dL  
• % of time  < 70 mg/dL  
• % of time  < 54 mg/dL  
• Standard deviation  
• Coefficient of variation   
 
• Percentage of time in hybrid closed -loop as proportion of overall device 
usage time  during Phase 2 , and separately during  Phase 3  
• Glucose management indicator (GMI) based on overall mean glucose  during 
Phase 2 , and separately during  Phase 3  will be compared to Phase 1  
• Insulin requirements during Phase 2 , and separately during  Phase 3 will be 
compared to Phase 1 : 
 
• Total daily insulin (TDI) ( units, units/kg)  
• Total daily basal insulin  (units, units/kg)  
• Total daily bolus insulin  (units, units/kg)  
 
• Change from baseline in BMI (kg/m2) at end of Phase 2 , and at end of  
Phase 3 . 
6.4 Exploratory Endpoints  
Analysis of t he following exploratory endpoints will be considered. The analyses 
may be used for internal research purposes and/or scientific presentations and/or 
manuscripts and may not all be provided in a regulatory submission :   
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 30 
• Number of hypoglycemic and hyperglycemic events as measured by [CONTACT_45924] -loop phase will be compared to the 
standard therapy phase  
• Glucose metrics from the system CGM during the hybrid closed -loop phase 
stratified by [CONTACT_45925]  
• Change from baseline in A1 C and BMI at the last follow -up visit given at 
least 6-weeks of participation  during Phase 2  
• Change from baseline in A1C after at least 6 weeks of continuous Phase 2 
participation , stratified by [CONTACT_25059] A1C (e.g. A1C ≥7.5%, ≥9.0%)  
• Proportion of subjects with A1C <7.0% at baseline and after at least 6 weeks 
of continuous Phase 2 participation ; similar analyses using A1C cutoffs of 
<7.5%, < 8.0% and <9.0%  
• Proportion of subjects with change from baseline in A1C after at least 6 
weeks of continuous Phase 2 participation  of >0.5% and >1.0%  
• Proportion of subjects who either had an improvement from baseline of 
>1.0% in A1C or A1C <7.0% after at least 6 weeks of continuous Phase 2 
participation  
• Percentage of time the CGM was used during the hybrid closed -loop phase  
• Number of meal and correction  boluses  
• Compare glycemic outcomes (e.g., time in range  <70 mg/dL, time in range  
>180 mg/dL) by [CONTACT_45926]  
• Compare glycemic outcomes (e.g., time in range  <70 mg/dL, time in range  
>180 mg/dL) by [CONTACT_45927] (i.e., days  with CGM 
informed bolus calculator used at least once and days without CGM 
informed bolus calculator use)   
• Post-prandial glucose response including time to peak glucose, peak 
glucose concentration, peak glucose excursion, to meals with bolus 
(challenge d ays 1 and 3) vs no bolus (challenge days 2 and 4)  
• Glycemic outcomes and other measures based on evaluable subjects (i.e., 
those subjects with at least 8 -weeks of data during the hybrid closed -loop 
phase)  
6.[ADDRESS_48464] - and careg iver-completed questionnaires will be used to evaluate 
general and disease -specific quality of life, and device usability. These include, 
but are not limited to:   
• WHO -5 
• EQ-5D 
• PAID  
• T1DDS  
• DSTQ  
• Hypoglycemia Confidence  
• HABS  
• PSQI  
• IDSS (T1)  
• SUS 
• INSPI[INVESTIGATOR_45874]™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 31 
• Human Factors Questionnaire  
• Clarke Questionnaire  
 
[ADDRESS_48465] 6 months  and are appropriate for pump therapy per 
investigator ’s assessment . Potential subject s will be selected at each clinical study site 
and screened accordingly. Clinical study sites will be advised  to: 
 
• Recruit subjects using insulin aspart, lispro, and glulisine also known as 
Humalog, Novolog, Adme log, and Api[INVESTIGATOR_27976]  
• Recruit at least 20% of subjects using MDI  
 
Every effort will be made to establish eligibility of the patient  prior to enrollment . Only 
patients  who appear to meet all eligibility criteria will be enrolled in the study.  Subject  
eligibility will be confirmed by [CONTACT_45928] a screening  visit at the clinical site. 
Blood draws will be collected as required to demonstrate study eligibility as noted 
below.  Laboratory results within the last [ADDRESS_48466] therapy phase of the pi[INVESTIGATOR_45875] .  
7.1 Visit 1  
Visit 1  will be conducted in person at the clinical study site. This visit will assess 
eligibility and will include : 
 
• Signing of i nformed consent /assent  
• Review of i nclusion/exclusion criteria  
• Screening  assessments  performed following  Table 2:  Schedule of 
Assessments  for Phase 1 and Phase 2  
 
Informed Consent /Assent  
Subjects who appear to meet the eligibility criteria will be asked to sign an 
Informed Consent Form (ICF) approved by [CONTACT_45929] (IRB) for participation in the study. A parent/guardian must sign the ICF for 
subjects <18 year s of age. Assent will also be obtained from subjects aged <18 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 32 
years per State requirements. Failure to provide informed consent/assent will 
render the subject ineligible for the study.  
Subjects must also have a signed HIPAA ( Health Insurance Portability an d 
Accountability Act)  release of protected health information (PHI). The release may 
be a stand -alone document or part of the informed consent.  
After informed consent /assent  is obtained, a subject identification number will be 
issued to uniquely identify e ach subject . The unique identifier will be used to 
identify the subject throughout the study and will be used for all source documents 
and electronic Case Report Forms (eCRFs).  
Inclusion Criteria  
Subject s must meet all of the following criteria in order to  be enrolled in the study:  
1. Age at time of consent 6 -70 years  
2. Subjects aged < [ADDRESS_48467] be living with parent/legal guardian  
3. Diagnosed with type [ADDRESS_48468] 6 months. Diagnosis is based 
on investigator’s clinical judgment  
4. Deemed appropriate for pump therapy per investigators assessment taking 
into account previous history of severe hypoglycemic and hyperglycemic 
events, and other comorbidities  
5. Investigator has confidence that the subject can successfully operate all 
study devices and is capable of adhering to the protocol  
6. Willing to use only  the following types of insulin during the study:  Humalog, 
Novolog, Admelog  or Api[INVESTIGATOR_45861]  
7. Must be willing to travel to and participate in meal and exercise challenges 
during 5-days of the hybrid closed -loop phase  
8. Willing to wear the system continuously throughout the study  
9. A1C <10% at screening visit   
10. Must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as 
the sole source of Dexcom data (with the exception of the Dexcom Follow 
App) during the hybrid closed -loop phase  
11. Subjects scoring ≥ [ADDRESS_48469] and who can be available ove rnight  
12. Able to read and speak English  fluently  
13. Willing and able to sign the Informed Consent Form (ICF) and/or has a 
parent/guardian willing and able to sign the ICF. Assent will be obtained  
from pediatric and adolescent  subjects  aged < [ADDRESS_48470] s who meet any of the following criteria will be excluded from the study:  
1. A medical condition,  which in the opi[INVESTIGATOR_871], would put the 
subject at an unacceptable safety risk 
2. History of severe hypoglycemia  (as defined in Section 12.3.3 ) in the past 6 
months  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 33 
3. History of DKA  (as defined in Section 12.3.4 ) in the past 6 months , 
unrelated to an intercurrent illness , infusion set failure  or initial diagnosis  
4. Diagnosed with sickle cell disease  
5. Diagnosed with hemophilia or any other bleeding disorders  
6. Plans to receive blood transfusion over the course of the study  
7. Currently d iagnosed with anorexia nervosa or bulimia  
8. Acute or c hronic kidney disease (e.g. estimated GFR < 45) or currently on 
hemodialysis  
9. History of adrenal insufficiency  
10. Has taken oral or injectable steroids within the past 8 -weeks or plans to 
take oral or injectable steroids during the course of the study  
11. Unable t o tolerate adhesive tape or has an y unresolved skin condition in 
the area of sensor or pump placement  
12. Plans to use  insulin other than U -100 insulin intended for use in the study 
device during the course of the study  
13. Use of  non-insulin anti -diabetic medica tion other than metformin  (e.g. 
GLP1 agonist, SGLT2 inhibitor, DPP -4 inhibitor, pramlintide)  
14. Current or known history of coronary artery disease that is not stable with 
medical management, including unstable angina, or angina that prevents 
moderate exercise despi[INVESTIGATOR_45862], or a history of 
myocardial infarction, percutaneous coronary intervention, or coronary 
artery by[CONTACT_45930] 12 -months.  
15. For subjects > 50 years old or with diabetes duration > 20 years, a bnormal 
electrocardiogram consistent with increased risk of arrhythmia, ischemia, 
or prolonged QT c interval (> 450 ms)  
16. Thyroid Stimulating Hormone (TSH) is outside of normal range with 
clinical signs of hypothyroidism or hyperthyroidism  
17. Pregnant or lactating, or is a woman of childbearing potential and not on 
acceptable form of birth control (acceptable includes abstinence, condoms, 
oral/injectable contraceptives, IUD or implant)  
18. Participati on in another clinical study using an investigational drug o r 
device  other than the Omnipod Horizon™ Automated Glucose Control  
System  within the preceding 30 -days or intends to participate during the 
study period    
19. Unable to follow clinical protocol for the duration of the study or is 
otherwise deemed unacceptable to participate in the study per the 
investigator’s clinical judgment  
Screening  Assessments  
 
Subject s who have signed the informed consent and  appear to meet the eligibility 
criteria will continue to the s creening  assessments  which will be performed at the 
clinical study site .   
Screening assessments must be completed within 30-days  prior to the start date 
of the hybrid  closed -loop phase  (assessments  do not need to be completed on the 
same day)  and include the following : 
• Medical history (including  prior and current medical cond itions and surgical 
history ) 
• Demographics (age, gender, race)  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 34 
• A1C*  
• Thyroid Stimulating Hormone (TSH) level (local laboratory)  
• Creatinine level (local laboratory)  
• Pregnancy test for women of childbearing potential  
• Review of c oncomitant medications  
• Height  
• Weight  
• Assessment of v ital signs  
• Electrocardiogram (if applicable, see exclusion criteria 15)  
• Questionnaire  (Table 4:  Questionnaires ) 
o Clarke  
▪ Used to assess impaired awareness of hypoglycemia  
• For Dexcom G6 users, a ssessment of whether subjects have met the 
CGM usage and data criteria  to participate in an abbreviated standard 
therapy phase (Visit 2 only) per Table 2:  Schedule of Assessments  for 
Phase [ADDRESS_48471] 80% CGM use (11.2 -days) duri ng any consecutive [ADDRESS_48472] 30 -days and  
o ≥ 2,016 CGM values during the 14 -days  
 
*Clinical sites will send the b lood specimens for A1C to a NGSP (National 
Glycohemoglobin Standardization Program) certified central laboratory .  A point of 
care (POC) A1C may be used to determine eligibility.   
The Clarke Questionnaire will be administered during the screening visit.  Subjects 
scoring ≥ [ADDRESS_48473] therapy assessments are 
completed per Visit 2  – see Table 2:  Schedule of Assessments  for Phase 1 and Phase 
2.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48474] therapy phase, subjects will be asked to perform the following:  
 
• Manage their diabetes at home per their usual routine  
• Administer meal boluses per their usual  dosing routine  
• Change their sensor if a sensor fails, or as needed  
• Calibrat e their CGM , if required, per the manufacturer’s instructions   
• Monitor their c api[INVESTIGATOR_30135] (BG) per usual routine  
• Give meal boluse s. The timing of the bolus delivery will be  per each subject’s 
typi[INVESTIGATOR_45876] . 
 
Extending standard therapy past [ADDRESS_48475] 
profile : 
 
• Current Dex com G6 user s 
• Non-G6 users  
• Pump Naïve users  
 
Current Dexcom G6 User s 
 
Current Dexcom G6 users will be required to participate in the assessments required as 
part of standard therapy  (ST1/Visit 2)  but may be exempt from  wear ing the study CGM  
for 14 -days if the following criteria are met : 
 
• Willing to provide 14-days of CGM data fr om the past 30 -days  
• Meet the success criteria of 80%  CGM use during any consecutive 14-days in the 
past 30 -days  
• Must have ≥ 2,[ADDRESS_48476] continuous glucose information over the 14 -day 
period.  
Pump Naïve  Users  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48477] therapy p hase.  A saline trial consists of wearing a 
cleared Omnipod® DASH System with the Pod filled with saline to simulate pump 
therapy. This would enable subjects to familiarize themselves with the basic concepts of 
basal and bolus insulin del ivery as well as provide the experience of wearing an on -
body device prior to their participation in the hybrid closed -loop phase , if they choose to 
do so .  This is optional and not required.  If a pump naïve subject is also a current G6 
user that meets the  criteria as stated above, the subject will complete the saline trial 
prior to enrollment in the study .  
8.[ADDRESS_48478] therapy phase.  All 
scheduled assessments will be performed according to  Table 2:  Schedule of 
Assessments  for Phase 1 and Phase 2 .  This visit will include : 
 
• Review of concomitant medications  
• Average total daily insulin (approximately over the past 7 days)  
• Average total daily basal  insulin  (approximately over the past 7 days)  
• Average total daily bolus insulin (approximately over the past 7 days)  
• Review of pump settings/MDI dosing  
• Assessment of AEs  
• Completion of questionnaires  (see Table 4:  Questionnaires  for specific 
requirements by [CONTACT_551]) : 
• WHO -5 
o Used to measure current mental well -being  
• EQ-5D 
o Used to measure quality of life  
• T1DDS  
o Used to mea sure four critical dimensions of distress  
• DTSQ s 
o Used to measure satisfaction with diabetes treatment regimens  
• Hypoglycemia Confidence Scale  
o Used to measure hypoglycemia unawareness, hypoglycemia 
frequency, severity and impact  
• HABS  
o Used to measure critical dimensions of hypoglycemia related 
concerns and confidence  
• PSQI  
o Used to measure sleep disturbance and usual sleep habits  
• IDSS (T1)  
o Used to measure patient satisfaction with their devices and impact 
on quality of life  
• SUS 
o Used to measure usability of a syst em 
• PAID -(Teen, Child)  
o Measures diabetes -related burden  
• Training on Glucagon administration and information on treatment of 
hypo/hyperglycemia    
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 37 
• All subjects are required to have access to glucagon and receive 
training on how to deliver the medication  
• Study device training  per manufacturer’s instructions  (CGM  - blinded , BG, 
and ketone meters)  
• Dispensing of CGM  (blinded  for non -G6 users ), BG, and ketone meter  
• QC testing of BG and ketone meter  
• Must pass as least one level of quality control testing prior to 
dispensing  
• CGM sensor placement ( Enrollment )   
• Approved anatomical locations for CGM sensor placement will be 
reinforced as well as the importance of using approved locations  
 
During this visit, s ubjects will be dispensed the follo wing supplies : 
• Dexcom transmitter  
• Dexcom receiver  
• Dexcom sensors  
• Contour® Next One b lood glucose meter  
• Contour® Next One b lood glucose meter test strips  
• Contour® Next One b lood glucose meter control solution  
• Lancets  
• Precision Xtra  blood ketone meter  
• Precision Xtra  blood ketone meter test strips  
• Precision Xtra  blood ketone meter control solution  
 
Subjects will be provided, by [CONTACT_779], information regarding treatment of hypoglycemia 
and hyperglycemia including sick day management and emergency manageme nt of 
severe hypoglycemia and diabetic ketoacidosis.  Subjects will be given contact 
[CONTACT_45931].  
If a subject is on MDI, the investigator will advise the subject on the treatment regimen 
to reduce insulin depending on the insulin action profile of injected doses  prior to the 
commencement of the hybrid closed -loop phase . MDI subjects will be required to ke ep 
a log to record daily doses of insulin during the standard therapy phase.   
8.2 Visit 3  
Visit 3 will be conducted in person at the clinical study site  up to one (1) day prior 
to the start of the hybrid closed -loop phase.  All scheduled assessments will be 
performed according to Table 2:  Schedule of Assessments  for Phase 1 and  
Phase 2 .  This visit will include : 
 
• Assessment of AEs  
• Assessment of whether subjects have met the CGM usage and data 
criteria  
 
Prior to the commencement of the hybrid closed -loop phase, subjects must meet 
the following criteria:  
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48479] 80% CGM use (11.2-days) during any consecutive [ADDRESS_48480] 30 -days and  
o ≥ 2,[ADDRESS_48481] therapy phase  and after all assessments are  performed according to  the Table 
2:  Schedule of Assessments  for Phase 1 and Phase 2 .  
During the hybrid -closed loop phase, subjects will be asked  to do the following:  
 
• Adjust pump and CGM parameters to optimize their insulin therapy in 
collaboration with the recommendations from the clinical study staff  
• Follow their pre -exercise management such as insulin reduction for meal 
boluses, consumption of snacks, or adjusting their insulin delivery settings  
• Treat themselves per their usual routine if they become hypoglycemic or 
hyperglycemic or have symptoms of ei ther at any time during the study  
• Consume meals and snacks of their own choosing. Subjects will be encouraged 
to estimate the grams of carbohydrates for each meal or snack per their usual 
routine. The estimate should be entered into the meal bolus calculat or. 
• Administer meal boluses per their usual  dosing routine  
• Participate in challenge visits as specified  
• Change their CGM per manufacturer’s instructions or sooner if necessary  
• Change the Pod at least once every 72 hours  
• Complete questionnaires (Table 4:  Questionnaires ) 
Subjects will have scheduled follow -up visits according to  Table 2:  Schedule of 
Assessments  for Phase 1 and Phase 2  and complete questionnaires according to Table 
4:  Questionnaires . Visits will be conducted either in person at the clinical study site or 
over the telephone or videoconference .  Subjects may also choose to use email or text 
as a substitute for their schedul ed telephone visit.  In the event of overlappi[INVESTIGATOR_45877], no visits occurring during Phase [ADDRESS_48482] ~13-weeks  (the 13 
weeks may not be continuous) . 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 39 
9.1 Challenge  Visits  
A sub set of s ubjects  will take part in the prescribed supervised challenge s per the 
defined sample sizes in Table 5:  Sample Size of Subjects Enrolled in Challenges  
until the  minimum  number of subjects for each cohort subset has b een satisfied . 
Subjects will participate in prescribed challenges during any consecutive [ADDRESS_48483] follow -up telephone visits 
12-36 hours after each non -consecutive visit.  Challenge visits may occur on the 
same date as any other Phase 2 visit. 
Table 5:  Sample Size of Subjects Enrolled in Challenges  
Cohort (Ages)  Minimum Number of 
Subjects (N)  
14-70 years  N=60 
6-13.9 years  N=100 
Subjects will travel to a central location each day where they will be closely 
monitored by [CONTACT_45932].  Alternatively, if subjects are 
self-isolating during the COVID -19 pandemic, they may complete these 
challenges at home if a companion or caregiver is present and communicate s 
completion of activities to the site staff by [CONTACT_45933]. Sites ca n 
supervise glucose levels by [CONTACT_45934].     
During the 5 -day exercise and meal challenges, subjects will be supervised by 
[CONTACT_45935]. 
Clinical site staff or companions/caregivers will be equipped with emergency 
supplies including glucose tablets, glucagon, and other supplies used for the 
treatment of diabetic emergencies. Subjects may participate in exercise if their 
CGM value is ≥70 mg/dL with the correspondi ng CGM trend either steady or 
increasing. Subjects will be discharged from each day of challenges when they 
meet the CGM criteria between 70 -300 mg/dL on two consecutive checks for the 
last 30 -minutes of their participation given that the CGM trend is not rapi[INVESTIGATOR_45878].    
Challenges can occur i n a group setting with multiple subjects .  
The challenges will include:  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 40 
Table 6:  Challenges  
Challenges  Day 
1 Day 
2 Day 
3 Day 
4 Day 
5 Day  
6 
High 
Carbohydrate 
Meal  
(≥ 60 grams)  X 
With Bolus  
Day 1 and 2 
Matched 
Meal  X 
No Bolus  
Day 1 and 2 
Matched 
Meal  X 
With Bolus  
Day 3 and 4 
Matched 
Meal  X 
No Bolus  
Day 3 and 4 
Matched 
Meal  X 
With Bolus   
Exercise to 
include both:  
• One-hour 
minimum 
of 
moderate 
or greater 
intensity 
exercise12 
• Two-hour 
minimum 
of mild  or 
greater  
intensity 
exercise27 X X X X X  
Follow -up 
Telephone 
Visit  
(12-36h post 
challenges)       X 
 
Moderate intensity exercise is defined using the CDC guidelines12 (Table 7): 
Table 7:  CDC Guidelines12 for Moderate Intensity Exercise  
 Children and 
Adolescents  Adults  Older Adults  
Moderate 
Intensity 
Activities  Brisk walking  
Bicycling  
Hiking  
Catching/throwing  Walking/jogging 2.5 
miles per hour 
Bicycling  
Aerobics  Walking/hiking  
Jogging  
Bicycling  
Aerobics  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 41 
Low intensity exercise is defined using the US Department of Health and Human 
Services Physical Activity Guidelines for Americans and includes waking non -
sedentary behaviors such as walking at 2.0 miles per hour, cooking activities , or 
light housekeepi[INVESTIGATOR_007]. 27 
During the challenge visits, s ubjects will be encouraged to : 
• Follow their pre -exercise management such as insulin reduction for meal 
boluses, consumption of snacks, or adjusting their insulin delivery 
settings .  
• Treat themselves per their usual routine if they become hypoglycemi c or 
hyperglycemi c or have symptoms of either at any time during the exercise 
challenge . 
Subjects will be offered a snack prior to their release from the site upon disch arge.  
Inability to complete the 5 -days of exercise due to an injury where participation 
may exacerbate the condition will not be considered a protocol deviation. Ability to 
participate will be up to the discretion of the investigator.  
9.2 Visit 4 
Visit 4 represents the commencement of Phase 2 ( hybrid closed -loop phase ) for 
subjects that did not participate in the prepi[INVESTIGATOR_45879]  1.  All scheduled assessments will be 
performed according to Table 2:  Schedule of Assessments  for Phase 1 and 
Phase 2 .  This visit will include:  
• Pregnancy test for women of childbearing potential  
• Review of concomitant medications  
• Average total daily insulin (approximately over the past 7 days)  
• Average total daily basal  insulin  (approximately over the past 7 days)  
• Average total daily bolus  insulin  (approximately over the past 7 days)  
• Pump settings/MDI dosing  
• Assessment of AEs  
• Initiation of Horizon Data Portal monitoring  
 
• Omnipod Horizon ™ System device training  conducted by [CONTACT_45936]  
o Subjects will be trained on operating Omnipod Horizon™ in both 
Manual and Automated Modes.  
o This will include first time device set -up with entry of basal profile, bolus 
calculator settings with insulin:carbohydrate ratio, target glucose and 
correction factor.  
o The Pod will be filled with the subject’s own U -100 rapid -acting insulin 
and placed on  body. Subjects will also be trained on use of Dexcom G6 
CGM, regardless of previous experience, setting up low (recommended 
to be 70 mg/dL  or higher ) and high glucose alerts (recommended to be 
300 mg/dL  or lower ) and entering transmitter serial number int o the 
Horizon App.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 42 
o Subjects may choose their desired target BG ranging between 110 -150 
mg/dL in increments of 10mg/dL, although the default and 
recommended setpoint is 120 mg/dL.   
o In addition, Omnipod Horizon™ has a novel bolus calculator feature 
that incorporates both the CGM value and trend into the suggested 
bolus amount. In general, if the CGM values are trending up or down, 
the calculator will add or subtract insulin from the suggested bolus 
amount to help keep BGs within target ran ge. 
 
• Dispense Omnip od Horizon™ System  
• Complaints/device deficiencies for CGM, BG and ketone meter  
• Device uploads for CGM, BG and ketone meter  
• Data review by [CONTACT_30223]  
• Removal of the subject’s personal insulin pump  (if applicable)  
o Investigators may use the Insulet -provided Pa tient Therapy Order Form 
(PTOF) as a guide to transition subjects from MDI to pump therapy 
(Appendix  A) 
If a subject is a current Dexcom G6 User and Visit 2 and Visit 4 occur on the same 
day, average total daily insulin  and pump settings/MDI dosing  only needs to be 
collected once.  Further, if Visit [ADDRESS_48484] will 
initiate their treatment marking their commencement of the hybrid closed -loop 
phase.  
9.3 Visit 5  
Visit 5 will be conducted  either  over the telephone or in person at the clinical 
study site on Study Day 2 ± 1-day for subjects commencing the hybrid closed -loop 
phase during  Visit 4.  For subjects extending their participation from the prepi[INVESTIGATOR_45880], the visit may be conducted in person at the clinical study  site or over the 
telephone . This visit will include : 
• Informed consent for subjects extending their participation from prepi[INVESTIGATOR_22735]  
(Informed Consent may occur at any time during the prepi[INVESTIGATOR_45881])   
• Establi shing eligibility for subjects extending their participation from 
prepi[INVESTIGATOR_22735]  
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as o cclusion alarms and system 
hazard alarms since last visit  
• Device uploa ds for BG and ketone meter for subjects extending their 
participation from prepi[INVESTIGATOR_45882]  
• Data review of Automated Mode use by [CONTACT_45937]™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 43 
9.4 Visit 6  
Visit 6  will be conducted either over the telephone or in person at the  clinical 
study site on Study Day 3  ± 1 day. This visit will include:  
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Data review of Auto mated Mode use by [CONTACT_30223]  
 
9.5 Visit 7 
Visit 7 will be conducted either over the telephone or in person at the clinical 
study site on Study Day  10 ± 3-days . This visit will include : 
 
• A pregnancy test for women of childbearing potential  (if visit is conducted 
in person at the clinical study site)  
• Review of concomitant medications  
• Assessment of vita l signs  (if visit is conducted in person at the clinical 
study site)  
• Assessment of AEs sinc e last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads  for BG and ketone meter  (if visit is conducted in person at 
the clinical study site)  
• Data review of Automated Mode use by [CONTACT_45938] n 
 
9.6 Visit 8 
Visit 8 will be conducted either over the telephone  or in person at the clinical 
study site  on Study Day  24 ± 3-days . This visit will include : 
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies su ch as occlusion alarms and system 
hazard alarms since last visit  
• Data review of Automated Mode use by [CONTACT_30223]  
 
9.7 Visit 9 
Visit 9 will be conducted either over the telephone or in person at the clinical 
study site on study day 38 ± 3-days . This visit will include : 
• A pregnancy test for women of childbearing potential  (if visit is conducted 
in person  at the clinical site) .  
• Review of concomitant medications  
• Assessment of vital signs  (if visit is conducted in person at  the clinical site)  
• Assessment of AEs since last visit  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 44 
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads  for BG and ketone meter  (if visit is conducted  in person  at 
the clinical site)  
• Data revi ew of Automated Mode use  by [CONTACT_30223]  
 
9.8 Visit s 10, 11 and  12 
Visit s 10, 11 and  12 will be conducted  either  over the telephone or in person at 
the clinical study site on Study Day  52, 66, and 8 0 ± 3-days . These visits will 
include : 
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Data review of Automated Mode use by [CONTACT_30223]  
 
9.9 Visit 1 3 (End of Phase 2 ) 
Visit 1 3 will be conducted either over the telephone or in person at the clinical 
study site on Study Day  94 ± 3 days .  This visit will include : 
• A1C (blood draw sent to NGSP laboratory)  
• Pregnancy test for women of childbearing potential  (if visit is conducted in 
person at the clinical site)  
• Review of concomitant medications  
• Height  (if visit is conducted in person at the clinical site)  
• Weight  (if visit is conducted in person at the clinical site)  
• Assessment of vital signs  (if visit is conducted in person at the clinical site)  
• Assessment of AEs since last visit  
• Completion of questionnaires  (See Table 4:  Questionnaires  for specific 
requirements by [CONTACT_551]) : 
• WHO -5 
• EQ-5D 
• T1DDS  
• DTSQ c  
• Hypo glycemia  Conf idence  Scale  
• HABS  
• PSQI  
• IDSS (T1)  
• SUS 
• PAID -(Teen, Child)  
• INSPI[INVESTIGATOR_21392] -(Adult, Youth, Parent)  
▪ Used to measure a caregiver’s experience of the support they 
receive  
• Human Factors (HF) Questionnaire  
▪ Measures trust in the Horizon System  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 45 
• Clarke  Questionnaire  
• Discontinuation of Horizon Data Portal monitoring  if not continuing into 
Phase 3  
• Return study devices  if not continuing into Phase 3 (Omnipod Horizon ™ 
System, CGM, BG and ketone meters)  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  
• Data review  of Automated Mode use  by [CONTACT_45939] [ADDRESS_48485] s not continuing to Phase 3 .        
9.10 Unscheduled Visits  (Phase 2)  
Aside from scheduled visits, subjects  may require an unscheduled visit either by 
[CONTACT_756]  (inclusive of email or text options)  or in person at the clinical study site . 
All scheduled assessments will be performed according to Table 2:  Schedule of 
Assessments  for Phase 1 and Phase 2 . This visit will include , at a minimum:  
 
• Review of conc omitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads  for BG and ketone meter (recommendation only if visit is 
conducted at the clinical site)  
• Data review  of Automated Mode use  by [CONTACT_45940] 2  study pause, subjects that wish to continue to use the 
Omnipod Horizon ™ System in Manual Mode or subjects that wish to go back to 
using their own system during the pause will have either telephone or in  person 
visits every 4 weeks ± [ADDRESS_48486] been in the pi[INVESTIGATOR_45883] -loop phase for ≥ [ADDRESS_48487] to coincide with a scheduled or an  unscheduled visit.    
 
Sites will ensure subjects that are continuing to use the system in Manual Mode 
do not ente r Automated Mode during the study pause.   
 
• Sites will be asked to check the Horizon Data portal once per week to make 
sure subjects have not entered Automated Mode  
• If a subject is found to be in Automated Mode, the subject will be given a 
warning. If the same subject is found to be in Automated Mode a second 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48488] clinical study staff 24 hours per 
day to report any study related problems . Subjects will be encouraged to call the clinical 
study site at any time with any concerns .  
 
9.11 Recommencing After a Pause  
The recommencement visit or visits may be conducted either over the telephone 
or in person at the clinical study site preferably within 5 business days of 
recommencing Phase 2 of the study . The assessments required prior to the 
recommencement of Phase 2 will include:  
 
• Informed consent (may be conducted over telephone or email  and will 
contain language for the study recommencement and the e xtension phase ) 
• Optional A1C (blood draw sent to NGSP laboratory)  
• Pregnancy test for women of childbearing potential . If subject is not able to 
attend in person, they may conduct the test at home and report result to 
the site.   
• Review of concomitant medic ations  
• Average total daily insulin (approximately over the past 7 days)  
• Average total daily basal insulin (approximately over the past 7 days)  
• Average total daily bolus insulin (approximately over the past 7 days)  
• Assessment of AEs  
• Return Horizon System to subject (if applicable)  
• Update of PDM software  by [CONTACT_45941] a new , 
updated  PDM  
• Resume Phase 2 of hybrid closed -loop including the following (as 
applicable):  
o Entry of Dexcom Transmitter ID into Horizon ™ PDM  
o Initiation of Horizon ™ Data Portal monitoring  
o Removal of the subject’s personal insulin pump  
• Complaints/device deficiencies for study devices  
• Device uploads for BG and ketone meter  (if visit is conducted in person at 
the clinical site)  
• Data review by [CONTACT_45942].  
For example, a subject that started Phase 2 (of hybrid closed -loop) on 01 February 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48489] resume s Phase 2  
on 01 May 2020, this date is equivalent to Day 29 of Phase 2 participation.  The next 
scheduled study visit wo uld be Visit 9 that should occur on Study Day 38 ± 3 days.  In 
this example, Visit 9 should occur between the 7  May and 13 May 2020, inclusive, with 
the optimal date being 10 May 2020. All subsequent visits will occur as scheduled.    
A total of up to 42 s ubjects will defer recommencement of Phase 2 to participate in a 
parallel study (G200018) to evaluate the safety and effectiveness of the Omnipod 
Horizon ™ CGM -informed bolus calculator.  Once the subset of subjects complete the 
study,  they will recommence Phase 2 of the Omnipod Horizon pi[INVESTIGATOR_2397] (G190270).    
 
9.12 Early Withdrawal  (Phase 2)  
Any subject  may withdraw early from the study at any time  for any reason . Upon 
withdrawal, assessments will be performed following  Table 2:  Schedule of 
Assessments  for Phase [ADDRESS_48490]’s participation  in the study if it is in the best interest of the subject or  if the 
Sponsor  or local regulatory agency ( e.g., FDA) terminates the study . 
 
The E arly Withdrawal visit will include : 
 
• A1C (blood draw sent to NGSP laboratory)  
• Review of concomitant medications  
• Height  
• Weight  
• Assessment of vital signs  
• Assessment of AEs since last visit  
• Completion of questionnaires  (see Table 4:  Questionnaires  for specific 
requirements by [CONTACT_551]) : 
• WHO -5 
• EQ-5D 
• T1DDS  
• DTSQ c  
• Hypo glycemia  Conf idence  Scale 
• HABS  
• PSQI  
• IDSS (T1)  
• SUS 
• PAID -(Teen, Child)  
• INSPI[INVESTIGATOR_21392] -(Adult, Youth, Parent)  
▪ Used to measure a caregiver’s experience of the support they 
receive  
• Human Factors (HF) Questionnaire  
▪ Measures trust in the Horizon System  
• Clarke  Questionnaire  
• Discontinuation of Horizon Data Portal monitoring  
• Return all study devices  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 48 
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads  for BG and ketone meter  
• Data review by [CONTACT_45943],  and their participation in the study will 
end. 
In the event of a subject ’s death duri ng the study, the subject ’s participation  will be 
considered terminated and the date of death  will be used as the date of study exit. 
10 HYBRID CLOSED -LOOP – PHASE 3  
The hybrid closed -loop Phase 3 extension will commence at Visit 13 upon conclusion 
of hybrid closed -loop Phase 2 and after all assessments are  performed according to  
Table 2:  Schedule of Assessments  for Phase 1  and Phase 2 . Phase 3 assessments 
are to be performed according to Table 3:  Schedule of Assessments for Phase  3. 
For subjects that do not extend their participation into the extension phase, the reason 
for study exit at Visit [ADDRESS_48491] occur on or any time before commencing that study interval ( e.g. consent 
for first [ADDRESS_48492] occur on or before Visit 19).  
During the hybrid -closed loop extension phase, subjects will continue to perform the 
following:  
 
• Adjust pump and CGM parameters to optimize their insulin therapy in 
collaboration with the recommendations from the clinical study staff  
• Follow their pre -exercise management such as insulin reduction for meal 
boluses, consumption of snacks, or adjusting their ins ulin delivery settings  
• Treat themselves per their usual routine if they become hypoglycemic or 
hyperglycemic or have symptoms of either at any time during the study  
• Consume meals and snacks of their own choosing. Subjects will be encouraged 
to estimate the grams of carbohydrates for each meal or snack per their usual 
routine. The estimate should be entered into the meal bolus calculator.  
• Administer meal boluses per their usual dosing routine  
• Participate in challenge visits as specified  
• Change th eir CGM per manufacturer’s instructions or sooner if necessary  
• Change the Pod at least once every [ADDRESS_48493] scheduled follow -up visits. Visits will be conducted either in person at 
the clinical study site or over the telephone.  Subjects may also choose to use email or 
text as a substitute for their scheduled telephone visit.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48494] approximately 12-
months.  
Subjects will be encouraged to call the clinical study site at any time wit h any concerns.  
10.1 Visit 14  
Visit 1 4 will be conducted  either over the telephone or  in person at the clinical 
study site  on Study Day 120 ± 5 days .  This visit will include : 
• Review of concomitant medications  
• Assessment of adverse events since previous visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  (if visit is conducted at the clinical 
site) 
• Data review of Automated Mode use by [CONTACT_30223]  
10.2 Visit 15  
Visit 15 will be conducted either over the telephone  or in person at the clinical 
study site  on Study Day 150 ±5 days.  This visit will include:  
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter (if visit is conducted at the clinical 
site) 
• Data review  of Automated Mode use  by [CONTACT_30223]  
10.3 Visit 16  
Visit 1 6 will be conducted either over the telephone or in person at the clinical 
study site on Study Day 180 ± 5 days.  This visit will include:  
• A1C (blood sample sent to NGSP laboratory)  
• A pregnancy test for women of childbearing potential  (if visit is conducted 
in person at the clinical site)  
• Review of conco mitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter (if visit is conducted at the clinical 
site) 
• Data review  of Autom ated Mode use  by [CONTACT_45937]™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 50 
10.4 Visit s 17 and 18  
Visit s 17 and 18 will be conducted either over the telephone  or in person at the 
clinical study site  on Study Day 210 ± 5 days and Study Day 240 ± 5 days, 
respectively .  These visits  will include:  
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter (if visit is conducted at the clinical 
site) 
• Data review of Automated Mode use by [CONTACT_30223]  
 
10.5 Visit 19  
Visit 19 will be conducted either over the telephone or in person at the clinical 
study site  on Study Day 270 ± 5 days.  This visit will include:  
• A1C (blood sample sent to NGSP laboratory)  
• Pregnancy test  for women of childbearing potential (if visit is conducted in 
person at the clinical site)  
• Informed Consent (consent for second 6 -month interval of Phase 3 may 
occur on or any time  before this visit)  
• Review of concomitant medicat ions 
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  
• Data review of Automated Mode use by [CONTACT_30223]  
 
10.6 Visit 20  
Visit 20 will be cond ucted either over the telephone or in person at the clinical 
study site on Study Day 315 ± 5 days .  This visit will include:  
• Review of concomitant medications  
• Assessment of AEs since previous visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter (if visit is conducted at the clinical 
site) 
• Data review of Automated Mode use by [CONTACT_30223]  
10.7 Visit 21  
Visit 21 will be conducted either over the telephone or in person a t the clinical 
study site on Study Day 360  ±5 days.  This visit will include:  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 51 
• A1c (blood sample  sent to NGSP laboratory)  
• Review of concomitant medications  
• Assessment of AEs since previous visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter (if visit is conducted at the clinical 
site) 
• Data review of Automated Mode use by [CONTACT_30223]  
10.8 Visit 22  
Visit 22 will be conducted either over the telephone or in person at the clini cal 
study site on Study Day 405  ± 5 days.  This visit will include:  
 
• Review of concomitant medications  
• Assessment of AEs since previous visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads f or BG and ketone meter (if visit is conducted at the clinical 
site) 
• Data review  of Automated Mode use by [CONTACT_30223]  
 
10.9 Visits 23 (end of study)  
Visit s 23 will be conducted in person at the clinical study site on Study Day 450 ± 
5 days. This visit will include:  
• A1c (blood sample  sent to NGSP laboratory)  
• Review of concomitant medications  
• Height  
• Weight  
• Assessment of AEs since previous visit  
• Return study devic es (Omnipod Horizon ™ System, CGM, BG and ketone 
meters)  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  
• Data review of Automated Mode use by [CONTACT_30223]  
 
10.10  Unscheduled Vi sits (Phase 3) 
Aside from scheduled visits, subjects may require an unscheduled visit either by 
[CONTACT_45944]. All scheduled assessments will be 
performed according to Table 3:  Schedule of Assessments for Phase  3. This visit 
will include, at a minimum:  
 
• Review of concomitant medications  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 52 
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Data review of Automated Mode use by [CONTACT_45945].  
 
10.11  Early Withdrawal  (Phase 3)  
Any subject  may withdraw early from the study at any time  for any reason . Upon 
withdrawal, assessments will be performed following Table 3:  Schedule of 
Assessments for Phase  3. The i nvestigato r may also terminate a subject’s 
participation  in the study if it is in the best interest of the subject or  if the Sponsor  
or local regulatory agency ( e.g., FDA) terminates the study . 
 
The Early Withdrawal visit will include:  
 
• A1C (blood sample sent to NGS P laboratory)  
• Review of concomitant medications  
• Height  
• Weight  
• Assessment of AEs since last visit  
• Return study devices (Omnipod Horizon ™ System, CGM, BG and ketone 
meters)  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms sinc e last visit  
• Device uploads for BG and ketone meter  
• Data review by [CONTACT_45946], and their participation in the study will 
end. 
In the event of a subject’s  death duri ng the study, the subject’s participation will be  
considered terminated and the date of death  will be used as the date of study exit. 
10.[ADDRESS_48495] to follow -up.      
 
11 SPONSOR REPRESENTATIVES  
One or more representatives of the Sponsor may be present at the hybrid closed -loop 
clinical study site visits under supervision of the investigator.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48496] of the risks are not unique to the study 
and are typi[INVESTIGATOR_45884], CGM , and BG meters . 
The known risks are as follows:  
• Hypoglycemia and/or hyperglycemia as a result of change in diet , activity,  
diabetes management or insulin regimen during  the study . 
• Hypoglycemia and/or hyperglycemia as a result of over or under delivery of 
insulin due to a  device defect, failure or malfunction of any of the system 
components . 
• Hypoglycemia , hyperglycemia , diabetic ketoacidosis, seizure, coma or death 
relate d to insulin administration, pump use or misuse, or Horizon™ System 
use or misuse . 
• Use of the Pod (Omnipod® tubeless, insulin delivery  pump) - Because the 
Pod uses only rapid -acting insulin, users are at increased risk for developi[INVESTIGATOR_45885]. If it is untreated, prolonged  
hyperglycemia can quickly lead to diabetic ketoacidosis (DKA) . DKA can 
cause symptoms such as breathing d ifficulties, shock, coma, or death.  
Further, occlusions can interrupt insulin delivery and lead to hyperglycemia 
or DKA. Other potential risks associated with using the Pod are:  
o Anaphylaxis  (allergic shock ) 
o Bruising at the Pod site  
o Bleeding at the Pod site  
o Erythema ( redness at the Pod site) 
o Excoriation  (raw skin at Pod site) 
o Pruritus (i tching ) 
o Induration  (hardening of the skin at the Pod site) 
o Infection  (can include heat, redness, swelling, pain, and drainage ) 
o Inflammation ( redness, swelling ) 
o Skin reaction to adhesive at the Pod site  
o Papu le (small, solid raised area on the skin similar to a pi[INVESTIGATOR_45886] ) 
o Pain or discomfort  
o Ulceration ( skin sores ) 
o Vesicles (blisters)  
• Use of the CGM - risk of bruising, infection, pain and/or bleeding at the site 
of insertion,  and skin site reaction to adhesive  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 54 
• On rare occasions, the CGM sensor may break and leave a small portion of 
the sensor under the skin that may cause redness, swelling, or pain at the 
insertion site , and may require surgical removal . 
• Blood sampling with fingerstick - minor discomfort and risk of infection at site 
of fingerstick  
There are several potential benefits from this study. The Omnipod Horizon™ 
System is designed to provide a utomated glucose control. The system is expected 
to reduce hypoglycemia without incurring an unacceptable increase  in 
hyperglycemia and mean glucose. The system is also expected to reduce the 
extent and  magnitude of hyperglycemia associated with meals. The  Omnipod 
Horizon™ System  uses a control -to-target strategy  that attempts to achieve and 
maintain a set target glucose level.  
12.2 Hypoglycemia/Hyperglycemia  
Subjects will be asked to treat per their usual routine if they suspect either 
hypoglycemia or hyperglyc emia, either by [CONTACT_45947] a 
fingerstick BG, symptoms, or perceived risk.  
Subjects will be encouraged to manage their hyperglycemia per their usual 
routine.  This includes checking for ketones using the study -approved ketone 
meter a nd administering a correction bolus if needed.   
In the event of unexplained hyperglycemia, where the CGM is >300mg/dL for 1h 
or >250 mg/dL for 2h, blood glucose (measured with BG meter) and ketones 
should be checked. If BG is ≥300 mg/dL and ketones are >1.0 mmol/L, an 
occlusion or dislodged cannula should be suspected. The Pod should be 
removed, and the subject will be instructed to replace the Pod. Subjects should 
contact [CONTACT_45948]. This prolonged  hyperglycemic event , defined as 
meter BG ≥300 mg/dL and ketones >1.0 mmol/L,  will be recorded as an adverse 
event and cause may be attributed to suspected occlusion if the cannula is in situ 
or dislodged cannula i f it has been pulled out. Pods will be requested to be 
returned to Insulet for analysis.  An Adverse Event form will be completed per the 
Reportable Adverse Events section below . 
12.3 Adverse Events  
12.3.1  Definitions  
Adverse Event (AE) : is defined as a ny untoward medical occurrence, unintended 
disease or injury, or any untoward clinical signs (including an abnormal laboratory 
finding) in subjects, users or other persons, whether or not related to the 
investigational medical device.  
NOTE 1: This includes ev ents related to the investigational medical device or the 
comparator.28 
NOTE 2: This definition includes events related to the procedures involved (an y 
procedure in the clinical investigation plan).28 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 55 
Serious Adverse Event (SAE):  Any untoward medical occurrence that:  
o Led to death  
o Led to serious det erioration in the health of the subject, that either 
resulted in:  
▪ a life -threatening illness or injury, or  
▪ a permanent impairment of a body structure or a body function, or  
▪ in-patient or prolonged hospi[INVESTIGATOR_059], or  
▪ medical or surgical intervention to pre vent life -threatening illness 
or injury or permanent impairment to a body structure or a body 
function.  
o Led to fetal distress, fetal death, or a congenital abnormality or birth defect.  
 
NOTE: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
proce dure required by [CONTACT_5745], without serious 
deterioration in health, is not considered a serious adverse event.[ADDRESS_48497] (UADE):  Any serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated 
with, a device, if that effect, problem, or death was not previously identified in 
nature, severity , or degree of incidence in the investigational plan or application 
(including a supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of 
participants.[ADDRESS_48498] (ADE): An adverse device effect (ADE) is an adverse 
event related to the use of an investigational medical device. 28  
NOTE 1: This definition includes any adverse event resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or 
opera tion, or any malfunction of the investigational medical device.28 
NOTE 2: This definition includes any event resulting from user error or from 
intentional misuse of the investigational medical device.28 
An event that occurs solely due to participant (i.e., user) error in which the device 
functions properly generally will not be considered an ADE unless it is determined 
that the instructions on the screen of the device or user manual (or similar training 
materials) may have contributed to the event (note: the event may still meet 
criteria for r eporting as an adverse event).  
Serious Adverse Device Effect (SADE):  A serious adverse device effect is 
defined as an adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event. 28 
Device Deficiency (DD) : A device deficiency is defined as a device related 
complaint or malfunction  or any inadequacy of a device with respect to its identity, 
quality, durability, reliability, safety or performance and includes misuse or use 
errors and inadequate labeling . A device deficiency  is something that happens to 
a device or is related to devic e performance, whereas an adverse event happens 
to a participant. A device deficiency may occur independently from an AE, or 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 56 
along with an AE. An AE may occur without a device deficiency or there may be 
an AE related to a device deficiency.  
Note: for repor ting purposes, sites will not be asked to distinguish between device 
complaints and malfunctions.   
For any event where there is suspi[INVESTIGATOR_45887], the 
Sponsor will request that the investigator return the device for evaluation.  
All device complaints or malfunctions involving any investigational component of 
the Omnipod Horizon™ System used in the study will be reported to the Sponsor 
within [ADDRESS_48499] associated with a reported device deficiency 
(PDM, Pod, and CGM) should be retained at the clinical site and returned to the 
Sponsor or CGM manufacturer for investigation and analysis.  
12.3.[ADDRESS_48500] therapy phase 
(i.e., insertion of the CGM sensor) and continue through the hybrid closed -loop 
phase  [ADDRESS_48501]’s participation has  ended. All adverse events must 
be followed until resolution, or until the AE has stabilized, or until the study has 
been completed.  
Pre-existing medical conditions or symptoms observed prior to the start time of the 
standard therapy phase will not be reco rded as an AE and should be collected in 
the subject’s medical history. In the event there is a change (i.e., worsening) in the 
pre-existing medical condition or symptoms after enrollment meeting the criteria of 
a reportable adverse event , then an AE must be reported.  
For this protocol, a reportable adverse event includes any untoward medical 
occurrence that meets one of the following criteria:  
1. An SAE  
2. An ADE unless excluded from reporting in Hypoglycemic Events and 
Hyperglycemic/Ketotic Events sections belo w 
3. An AE occurring in association with a study procedure  
4. An AE not related to a study device issue which leads to temporary or 
permanent discontinuation of the study device  
5. An AE that affects the participant’s ability to complete any study 
procedures  
6. An AE for which a visit is made to a hospi[INVESTIGATOR_3409]   
7. Hypoglycemi c Events as defined below  
8. Hyperglycemia/Ketotic Events as defined  
Skin reactions from sensor or pod placement are only reportable if severe and/or 
required treatment.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 57 
For the purpose of this protocol, mild symptoms of hypoglycemia and 
hyperglycemia (i.e., clinically non -significant) or blood glucose values out of the 
normal range (whether or not they resulted in delayed meals or correction 
boluses) will not be reported as AEs u nless determined to meet the reportable 
criteria in the Hypoglycemic Events and Hyperglycemic/Ketotic Events sections 
below.  
All reportable AEs —whether volunteered by [CONTACT_2299], discovered by [CONTACT_45949], or detected through physical examination, 
laboratory test, or other means —will be reported on an AE eCRF .  
12.3.3  Hypoglycemic Events  
Hypoglycemia is only  reportable as an adverse event when one of the following 
criteria  is met:   
• Sever e Hypoglycemia: The event required assistance of another person 
due to altered consciousness,  and required another person to actively 
administer carbohydrate, glucagon, or ot her resuscitative actions25. This 
means that the participant was impaired cognitively to the point that he/she 
was unable to treat himself/herself, wa s unable to verbalize his/her needs, 
was incoherent, disoriented, and/or combative, or experienced seizure or 
loss of consciousness. These epi[INVESTIGATOR_45888].  If plasma 
glucose measurements are not available during such an event, 
neurological recovery attributable to the restoration of plasma glucose to 
normal is considered sufficient evidence that the event was induced by a 
low plasma glucose concentration.  
• Hypoglycemia res ulting in an SAE that may not otherwise meet the 
definition of Severe Hypoglycemia defined above.  
When a hypoglycemic event meets the above reporting requirements, an Adverse 
Event Form should be completed. A severe hypoglycemia event should be 
considered a serious adverse event  and follow the SAE  reporting requirements.  
 
12.3.4  Hyperglycemic/Ketotic Events  
Hyperglycemia is only reportable as an adverse event when any of the following 
criteria is met:   
• The event involved DKA, as defined by [CONTACT_45950] (DCCT)24 and described below  
• Evaluation or treatment was obtained at a health care provider facility for 
an acute eve nt involving hyperglycemia or ketosis, or the participant 
contact[CONTACT_45951]/ketosis  
• Prolonged hyperglycemia: defined as meter BG ≥300 mg/dL and ketones 
>1.0 mmol/L  
• Hyperglycemi a resulting in an SAE that may not otherwise meet the above 
criteria  
 
Hyperglycemic events are classified as DKA24 if all of the following are present:  
• Symptoms such as polyuria, polydipsia, nausea, or vomiting;  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 58 
• Serum ketones >1.5 mmol/L or large/moderate urine ketones;  
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate 
<15; and  
• Treatment provided in a health care facility  
 
When a hyperglycemia/ketotic event meets the above reporting requirements, 
Adverse Event Form should be completed.  
 
Events meeting DKA criteria should be considered a serious adverse event  and 
follow the SAE  reporting requirements. Hyperglycemia events no t meeting criteria 
for DKA generally will not be considered as serious adverse events unless one of 
the SAE criteria above is met.  
 
12.3.5  Relationship of Adverse Event to Investigational Device  
The investigator will be responsible for making a determination on t he causal  
relationship of the AE. Specifically, the investigator will report whether the AE was 
related to study procedures and/or related to the investigational device . 
To ensure consistency of adverse event causality assessments, investigators 
should app ly the following general guideline when determining whether an 
adverse event is related . 
The causal relationship to the study procedures and the investigational device for 
each adverse event will be rated as follows:  
• Unrelated : The event is not related to  the procedures or the investigational 
device.  
• Possibly Related : The temporal sequence is such that the relationship is 
not unlikely or there is no contradicting evidence that can reasonably 
explain the subject’s condition. There is a possibility of any relation 
between the event and the procedures or the investigational device.  
• Related : The temporal sequence is relevant or the event abates upon 
completion of the procedure/  investigational device, or the event cannot be 
reasonably explained by [CONTACT_423]’s condition or comorbidities. The 
event is related or most likely ass ociated with the procedures or the 
investigational device.  
 
12.3.6  Severity (Intensity) of Adverse Events  
The severity (intensity) of an adverse event will be rated on a three -point  scale: (1) 
mild, (2) moderate, or (3) severe. A severity assessment is a clinical determination 
of the intensity of an event. Thus, a severe adverse event is not necessarily 
serious. For example, itching for several days may be rated as severe, but may 
not be clinically serious.  
• MILD: Usually transient, requires no special treatment, and does not 
interfere with the participant’s daily activities.  
• MODERATE: Usually causes a low level of inconvenience, discomfort or 
concern to the participant and may interfere with daily activities but  is 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 59 
usually ameliorated by [CONTACT_45952].  
• SEVERE: Interrup ts a participant’s usual daily activities, causes severe 
discomfort, may cause discontinuation of study device, and generally 
requires systemic drug therapy or other treatment.  
 
12.3.7  Outcome of Adverse Events  
The outcome of each reportable adverse event will be  classified by [CONTACT_45953]:  
• RECOVERED/RESOLVED - The participant recovered from the AE/SAE 
without sequelae. Record the AE/SAE stop date.  
• RECOVERED/RESOLVED WITH SEQUELAE - The event persisted and 
had stabilized without further anticipated change in the event status . 
Record the AE/SAE stop date.  
• FATAL - A fatal outcome is defined as the SAE that resulted in death. Only 
the event that was the cause of death should be reported as fatal.  
AEs/SAEs that were ongoing at the time of death; however , were not the 
cause of death, will be recorded as “resolved” at the time of death.  
• NOT RECOVERED/NOT RESOLVED (ONGOING) - An ongoing AE/SAE 
is defined as the event was ongoing with an undetermined outcome.  
• An ongoing outcome will require follow -up by [CONTACT_45954]/SAE  or until participant 
completes the study . 
• The outcome of an ongoing event at the time of death that was not the 
cause of death, will be updated and recorded as “resolved” with the 
date of death rec orded as the stop date.  
• UNKNOWN - An unknown outcome is defined as an inability to access the 
participant or the participant’s records to determine the outcome (for 
example, a participant that was lost to follow -up). 
 
If any  UADEs  are ongoing when a partic ipant completes the study (or withdraws),  
the subject  will continue to be followed until the event resolves or has no prospect 
of improvement or change, even after the participant has completed all applicable 
study visits/contacts , unless that subject has withdrawn their consent . For all other 
reportable adverse events, data collection will end at the time the participant 
completes the study. Note: Participants should continue to receive appropriate 
medical care for an adverse event after their participatio n in the study ends.  
12.4 Reportable Device Issues  
Device complaints and device malfunctions will be reported except in the following 
circumstances. These occurrences are expected and will not be reported on a 
Device Deficiency Form : 
• CGM sensor or Pod lasting fewer days than expected per manufacturer  
• CGM tape  or Pod  adherence issues  
• Battery lifespan deficiency due to inadequate charging or extensive wireless 
communication  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 60 
• Intermittent device component disconnections/communication failures not 
requiring system replacement or workaround/resolution not specified in user 
guide/manual.  
• Device issues clearly addressed in the user guide manual that do not require 
additional troubleshooting  
12.[ADDRESS_48502] be reported to the Sponsor/CRO within 2 business days  of the site 
becoming aware of the event. This can occur via phone or email, or by [CONTACT_45955] . If the form is not initially completed, it should be competed as 
soon as possible after there is sufficient information to evaluate the event. All 
other reportable AEs should be submitted by [CONTACT_45956] 5 
business days of the site becoming aware of the event.  
Each principal investigator  [INVESTIGATOR_45889]/her 
Institutional Review Board or Ethics Committee.  
Upon receipt of a UADE report, the Sponsor will investigate the UADE  and if 
indicated, report the results of the investigation to all participating investigators, 
overseeing IRBs, and the FDA within 10 business  days of the Sponsor becoming 
aware of the UADE per 21CFR 812.46(b). Copi[INVESTIGATOR_45890], regulatory authorities, and Sponsor must 
be retained with study records.  
The Medical Monitor must notify the DSMB o f any UADEs and determine if the 
UADE presents an unreasonable risk to participants. If so, the Sponsor  must 
ensure that all investigations, or parts of investigations presenting that risk, are 
terminated as soon as possible but no later than [ADDRESS_48503] 
notice of the UADE.  
Device deficiencies  will be handled by [CONTACT_45957]. In the case of a Dexcom CGM transmitter or sensor device malfunction, 
information will be forwarded to Dexcom by [CONTACT_14523], to be handled by 
[CONTACT_45958]’s  complaint management system.  
If the subject is hospi[INVESTIGATOR_45891], then a 
copy of the hospi[INVESTIGATOR_45892]. In case of death, the investigator must make every effort to 
obtain a copy of the death certificate to submit to the Sponsor. When submitting 
copi[INVESTIGATOR_45893], all subject identifying information must be red acted and 
only the unique subject number will be used to label the forms for identification 
purposes.  
For any event where there is suspi[INVESTIGATOR_45887], the 
investigator  will return  the device for evaluation  when possible . 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48504] (DSMB) will be informed of all cases of 
severe hypoglycemia and diabetic ketoacidosis irrespective of device relationship, 
all UADEs during the study and will review compi[INVESTIGATOR_45894]. The DSMB also wil l be informed of any SADEs and ADEs not meeting 
criteria for a UADE if the Medical Monitor requests the DSMB review. The DSMB 
can request modifications to the study protocol or suspension or outright stoppage 
of the study if deemed necessary based on the t otality of safety data available. 
Details regarding DSMB review will be documented in a separate DSMB Charter . 
 
12.[ADDRESS_48505] , or all study 
subjects , to stop using the study device or to only use in Manual Mode. Should all 
study subjects  be required to stop using the study device or to o nly use in Manual 
Mode due an UADE, use of the study device or Automated Mode will not be 
restarted until approval is received from the IRB, DSMB and FDA.  
Use of the study device by a participant will be discontinued if any of the following 
occur:  
• The investigator believes it is unsafe for the participant to continue on the 
intervention. This could be due to the development of a new medical 
condition or wors ening of an existing condition; or participant behavior 
contrary to the indications for use of the device that imposes on the 
participant’s safety . 
• The participant requests that the treatment be stopped  
• Participant pregnancy  
• Two distinct epi[INVESTIGATOR_45895]  
• Two distinct severe hypoglycemia events as defined above  
• One epi[INVESTIGATOR_45896] a single DKA 
or severe hypoglycemia event will  be that (1) the site investigator believes that 
the event is explainable, unlikely to recur, and that it is safe for the participant to 
continue to use the system and (2) the Medical Monitor concur s. If the Medical 
Monitor determines that the occurrence o f the event indicates that it is not safe 
for the participant to continue to use the system, use will be discontinued,  and the 
subject will be withdrawn from the study . 
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 62 
12.7.2  Criteria for Suspending or Stoppi[INVESTIGATOR_45897] 2  will b e determined by [CONTACT_45959], who 
will assess the specific event rates for DKA and severe hypoglycemia from the 
study at specific timepoints relative to published rates from large, population -
based datasets. Stoppi[INVESTIGATOR_45898] 3 extension.    
 
In consideration of adverse events rates occurring in this proposed study, the 
rates will be assessed relative to published rates from Foster et. al.10 and Miller et. 
al.26 to determine whether severe hypoglycemia or diabetic ketoacido sis are within 
expected rates during this study  Table 8:  T1D Exchange Rates of Severe 
Hypoglycemia and Diabetic Ketoacidosis 10,26 provides a summary of these 
published rates.  
 
Table 8:  T1D Exchange Rates of Severe Hypoglycemia and Diabetic 
Ketoacidosis10,26 
Adverse Event  Frequency of subjects to experience ≥ 1 
event extrapolated from T1DX registry 
2016 -2018, 2013 -2014  
Severe hypoglycemia (loss of consciousness or 
seizure)  4-5% < 18 years  
7% ≥ 18 years  
Diabetic ketoacidosis (overnight hospi[INVESTIGATOR_059])  3-4% < 18 years   
2-3% ≥ 18 year s  
 
For unanticipated adverse device effects (UADEs), the DSMB  will determine 
whether the study should proceed or not based upon risk of additional serious 
adverse events and the underlying root cause analysis of the UADE.   
 
Study activities could be similarly suspended if the manufacturer of any 
component of the inv estigational  study device requires stoppage of device use for 
safety reasons (e.g. product recall).   
 
The affected study activities may resume if the underlying problem can be 
corrected by a protocol or system modification that will not invalidate the results 
obtained prior to suspension.  
 
The study Medical Monitor will review all adverse events that are reported during 
the study, and the DSMB  will review all cases of severe hypoglycemia, DKA and 
UADEs as well as compi[INVESTIGATOR_27985]. The Medical Monitor 
and/or DSMB may recommend suspension of study activities or stoppage of the 
study  to the Sponsor if deemed necessary based on the totality of safety data 
available.  
12.[ADDRESS_48506] (DSMB)  
The DSMB will be established prior to the  first enrollment and consist, at a 
minimum, of two physicians and one statistician independent  from the Sponsor  
and study. The physicians will have relevant therapeutic and medical expert[INVESTIGATOR_18700]. 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48507] terminations, and /or subject withdrawals related to device or 
proce dure safety. In addition, the DSMB members will be notified upon the 
occurrence of any UADEs to  determine whether the study should proceed or not 
based upon risk and may request an ad hoc meeting to discuss. At minimum, the 
DSMB will conduct reviews after [ADDRESS_48508] 
completed a minimum of 10 -days of the hybrid closed -loop phase  (and prior to 
commencement of Pi[INVESTIGATOR_9205] 2 for any subjects that did not participate in 
Prepi[INVESTIGATOR_9205] 2), at the concl usion of the prepi[INVESTIGATOR_45899], after at least [ADDRESS_48509] completed study visit 7 (24 ± 3 days of HCL therapy), and 
after the end of Phase [ADDRESS_48510] of the DSMB, Sponsor  or Medical Monitor. At the conclusion  of 
each meeting, the DSMB will make a recommendation to the Sponsor  concerning 
the continuation, modification, and/or termination, of the study  and/or a statement 
regarding their overall assessment of device safety  and continuation of the pi[INVESTIGATOR_45880] . The final decision regarding the continuation, modification or termination of 
the study will reside with the Sponsor . Responsibilities, qualifications, membership 
and committee procedures, including the final stoppi[INVESTIGATOR_004], will be outlined in the 
DSMB Cha rter. 
12.[ADDRESS_48511] with the clinical study . 
 
Specific re sponsibilities of the Medical Monitor include:  
 
• Review of all adverse events reported during the study  
• Review all serious study procedure -related and/or investigational device -
related adverse events to determine if the adverse event warrants 
consideration as a UADE and facilitate the reporting of UADEs if applicable  
• Adjudicate the following(a) all SAEs; (b ) any events of Diabetic Ketoacidosis 
or Severe Hypoglycemia; (c) all AEs reported by [CONTACT_45960]; and/or (d) any additional 
events as requested by [CONTACT_1034].  
• The specified events will be adjudic ated to determine:  
o event relatedness to the study procedures and/or the 
investigational device  
o event categorization and assess seriousness and severity  
o whether an adverse event is anticipated or unanticipated  
The adjudication decision of the Medical Monito r will be used for the final 
classification of events, including relatedness to the study procedures and/or the 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48512] labeling, and publications or presenta tions.  
 
The Medical Monitor’s roles and responsibilities are described in the Safety 
Management Plan  (SMP) .  
 
[ADDRESS_48513] been 
collected during a study pause (including but not limited to CGM readings from the 
Horizon system while i n Manual Mode), will be excluded from analyses.  
Continuous Phase 2 participation refers to the length of time on the Horizon 
system (either in Automated on Manual Modes ) and is calculated  as: 
• Commence ment of Phase 2 until a study pause  (for subjects who s tarted 
Phase 2 prior to a study pause)  
• Recommencement until discontinuation from the Horizon system or end of 
Phase 2 (for subjects who started Phase 2 prior to a study pause)  
• Commencement of Phase 2 until discontinuation from the Horizon system 
or end of Phase 2 (for subjects who started Phase 2 after a study pause)  
If a subject has ≥6 weeks on the Horizon system during Phase 2 prior to  a study 
pause and ≥6 weeks on the Horizon system during Phase 2 after the 
recommencement, the longer interval will be used for analysis  of A1C . 
Specifically, the A1C associated with the longer interval, if available, will be used 
for the analysis of the A1C endpoints.  
13.2 Objectives and Endpoints  
13.2.1  Primary Safety Objective  
The primary safety objective of the study is to evalua te the safety of the Omnipod 
Horizon ™ System in patients with type 1 diabetes . 
 
[IP_ADDRESS]  Primary Safety Endpoints  
The primary safety objective will be evaluated  by [CONTACT_45909] 2 , and  separately during  Phase 3 :  
 
• Incidence r ate of s evere hypoglycemia (events per person months ) 
• Incidence r ate of diabetic ketoacidosis ( DKA) (events per person months ) 
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 65 
13.2.2  Primary Effectiveness Objective  
The primary effectiveness objective of this study is to evaluate the effectiveness  of 
the Omnipod Horizon ™ System  
 
[IP_ADDRESS]  Primary Effectiveness Endpoints  
There are two primary  effectiveness  endpoints.  
 
• A1C after at least 6 weeks of continuous Phase 2 participation  compared 
to baseline  
• A1C at Visit 16 , 19, 21, and 23  compared to baseline  
• Percentage of time in range (70-180 mg/dL ) during Phase 2 and 
separately during Phase 3 of the hybrid closed -loop phase  as compared to 
Phase 1 ( standard therapy ) 
 
A1C – Phase [ADDRESS_48514]’s participation in Phase 2.  
 
The change in A1C is calculated as A1C  at follow -up minus baseline A1C  (where 
negative change indicates decrease or improvement in A1C) . The null hypothesis 
associated with this endpoint states that the mean change in A1C is greater than 
or equal to zero. Rejection of the null hypothesis indicates that the observed data 
support the alternative hypothesis that the mean change in A1C is less than zero . 
 
The hypotheses associated with the first primary endpoint are defined as:  
H0: µ ≥ 0 
H1: µ < [ADDRESS_48515] differences in A1C from baseline to follow -
up.  
 
A1C – Phase 3  
 
A1C at Visit 16 (~6 months total HCL participation)  will be compared to baseline 
A1C as measured by [CONTACT_45961] A1C at follow -up visit for each subject.  
 
The change in A1C is calculated as A1C at follow -up minus baseline A1C.  There 
are no hypotheses associate d with this endpoint.   
 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 66 
 
Percentage of Time in Range 70 -180 mg/dL  – Phase 2  
 
The percentage of time in range 70 -180 mg/dL during Phase 2of the hybrid 
closed -loop phase will be compared to standard therapy by [CONTACT_45962] 2of hybrid closed -loop and 
Phase 1 ( standard therapy ) for each subject. The change in percentage of time in 
range 70 -180 mg/dL is calculated as the percentage of time in range during Phase 
2 minus the percentage of time in range during Phase 1  (where positive change 
indicates increased time in range) . The null hypothesis assoc iated with this 
endpoint states that the mean change in percentage of time in range 70 -180 
mg/dL is less than or equal to zero. Rejection of the null hypothesis indicates that 
the observed data support the alternative hypothesis that the mean change in 
percentage of time in range 70 -180 mg/dL is greater than zero.  
 
The hypotheses associated with the this primary endpoint are defined as:  
H0: µ ≤ 0 
H1: µ > [ADDRESS_48516] differences in percentage of time in range 
70-180 mg/dL during  Phase 2 of  hybrid closed -loop phase  compared to Phase 1 . 
 
Percentage of Time in Range 70 -180 mg/dL  – Phase 3  
 
The percentage of time in range 70 -180 mg/dL during Phase [ADDRESS_48517] therapy by [CONTACT_45963] e change 
between the time in range percentages between Phase 3 of hybrid closed -loop 
and Phase 1 (standard therapy) for each subject. The change in percentage of 
time in range 70 -180 mg/dL is calculated as the percentage of time in range 
during Phase 3 min us the percentage of time in range during Phase 1. There are 
no hypotheses associated with this endpoint.   
 
13.2.3  Secondary Objective  
The secondary objective of the study is to evaluate additional glycemic measures 
of effectiveness  of the Omnipod Horizon ™ Syste m. 
13.2.[ADDRESS_48518] 
endpoints with prespecified hypotheses:  
• Glucos e metrics from system CGM  during the hybrid closed -loop phase for 
Phase 2  will be compared to Phase 1  overall : 
• % of time  > 180 mg/dL  
• % of time  < 70 mg/dL  
Additional per subject secondary endpoints without  prespecified hypotheses used 
to evaluate  the secondary objective include:   
• A1C:  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48519] 8 weeks of continuous Phase 2 participation at 
the end of Phase 2 (Visit 13), at 6 months (Visit 16) , and at the 
end of Phase 3 (Visit 23; approximately 15 months ) 
o Change from baseline in A1C after at least [ADDRESS_48520] 8 weeks of continuous Phase 
2 participation at the end of Phase 2 (Visit 13), at 6 months (Visit 
16), and at the end of Phase 3 (Visit 23; approximately 15 
months )  
o Proportion of subjects demonstrating an improvement from 
baseline in A1C after at  least [ADDRESS_48521] 8 weeks of continuous Phase 2 
participation at the end of Phase 2 (Visit 13), at 6 months (Visit 
16), and at the end of Phase 3 (Visit 23; approximately 15 
months )  
 
• Glucose metrics from sy stem CGM during the hybrid closed -loop phase 
during  Phase 2 , and separately during  Phase 3 will be compared to Phase 1  
during the day, overnight, and overall:  
 
• Mean glucose  
• % of time  in range 70 -180 mg/dL  
• % of time  in range 70 -140 mg/dL  
• % of time  > 180 mg/dL  
• % of time  ≥ 250 mg/dL  
• % of time ≥ 300 mg/dL  
• % of time  < 70 mg/dL  
• % of time  < 54 mg/dL  
• Standard deviation  
• Coefficient of variation  
 
• Percentage of time in hybrid closed -loop as proportion of overall device 
usage t ime during Phase 2 , and separately during Phase 3  
• Glucose management indicator (GMI) based on overall mean glucose  during 
Phase 2 , and separately during Phase 3 will be compared to Phase 1  
• Insulin requirements during Phase 2 , and separately during Phase 3  will be 
compared to Phase 1 : 
 
• Total daily insulin (TDI) ( units, units/kg)  
• Total daily basal insulin  (units, units/kg)  
• Total daily bolus insulin  (units, units/kg)  
 
• Change from baseline in BMI (kg/m2) at end of Phase 2 , and at end of  Phase 
3 
 
Percentage of Time in Range >180 mg/dL  
 
The percentage of time in range >180 mg/dL during  Phase [ADDRESS_48522] therapy  (Phase 1)  by [CONTACT_45964] [ADDRESS_48523]. The change in percentage of time in range >180 mg/dL is calculated as 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 68 
the percentage of time in range during Phase 2  minus the percentage of time in 
range during Phase 1 . The null hypothesis associated with th is endpoint states 
that the mean change in percentage of time in range >180 mg/dL is greater than 
or equal to zero. Rejection of the null hypothesis indicates that the observed data 
support the alternative hypothesis that the mean change in percentage of t ime in 
range >180 mg/dL is less than zero.  
 
The hypotheses associated with this secondary effectiveness endpoint are defined 
as: 
H0: µ ≥ 0 
H1: µ < [ADDRESS_48524] differences in percentage of time in range 
>180 mg/dL during Phase [ADDRESS_48525] 
therapy phase  (Phase 1) . 
 
Percentage of Time in Range <70 mg/dL  
 
The percentage of time in range <70 mg/dL during  Phase [ADDRESS_48526] therapy (Phase 1) by [CONTACT_45962] [ADDRESS_48527]. The change in percentage of time in range <70 mg/d L is calculated as the 
percentage of time in range during Phase 2  minus the percentage of time in range 
during Phase 1 . The null hypothesis associated with this endpoint states that the 
mean change in percentage of time in range <70 mg/dL is greater than o r equal to 
zero. Rejection of the null hypothesis indicates that the observed data support the 
alternative hypothesis that the mean change in percentage of time in range <70 
mg/dL is less than zero.  
 
The hypotheses associated with this secondary effectiven ess endpoint are defined 
as: 
H0: µ ≥ 0 
H1: µ < [ADDRESS_48528] differences in percentage of time in range 
<70 mg/dL during Phase [ADDRESS_48529] 
therapy phase  (Phase 1) . 
 
13.3 Sample Size  
This is a single -arm, multi -center, prospective study. The sample size and study 
duration were  determined to allow for adequate safety profile of the investigational 
device . The study will be claimed successful if rates of Severe Hypoglycemia  and 
DKA durin g Phase 2 are considered acceptable compared to published rates.  
In addition,  a statistically powered sample size was determined for the two Phase 
2 primary effectiveness endpoints. Since each of the  Phase 2  primary 
effectiveness endpoints will be evaluate d separately, the significance  level will be 
adjusted so that the overall type I error can be maintained at one -sided 2.5% and 
each endpoint will be tested at one -sided 1.25%.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48530] 6 Weeks of Continuous 
Phase 2 Participati on Compared to Baseline  
The sample size estimation is based on the following assumptions:  
• Mean difference between paired observations of A1C after at least 6 
weeks of continuous Phase 2 participation  compared to baseline  is -
0.5%  
• Standard deviation of the difference between paired observations of A1C 
after at least 6 weeks of continuous Phase 2 participation  compared to 
baseline is 0.8%  
• Power of 90% and one -sided significance level of 1.25% 
The estimates for the mean difference and standard deviation of the difference 
between the paired observations were obtained from previous Omnipod studies, 
where subjects experienced a mean change in A1C of 0.38% over 3 months  
(standard pump therapy only) , from 8.1 to 7.7%, n=85  (data on file) . Based on the 
above assumptions, 35 subjects are required to provide  evaluable data.  
13.3.2  Primary Endpoint of Percentage of Time in Range 70 -180 mg/dL  
During  Phase 2 of  Hybrid Closed -Loop  Compared to Phase  1 
The sample size estimation is based on the following assumptions:  
• Mean difference between paired observations of percentage of time in 
range 70 -180 mg/dL during Phase 2  of hybrid closed -loop compared to 
the Phase 1  is 10%  
• Standard deviation of the difference between paired observations of 
percentage of time in range 70 -180 mg/dL during Phase 2 of  hybrid 
closed -loop compared to Phase 1  is 15%  
• Power of 90% and one -sided significance level of 1.25%  
The estimates for the mean di fference and standard deviation of the difference 
between the paired observations were obtained from recent Omnipod studies, 
G170012  and G170143 , where subjects experienced a mean change in 
percentage of time in range 70 -180 mg/dL of 10.0 ± 15.1% and 13.8 ± 14.6%, 
respectively. Based on the above assumptions, 31 subjects are required to 
provide evaluable data.  
To gather adequate safety and effectiveness data on the performance of the 
Omnipod Horizon™ System, a total of up to 240 subjects will be enrolled i n the 
study in order to obtain a minimum of 200 evaluable subjects.  
Subjects will be enrolled at up to 20 clinical study sites . No single site should 
enroll more than 24 subjects for each age cohort.   
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 70 
A subset of subjects will take part in the prescribed exercise challenges per the 
defined sample sizes until the minimum number of subjects for each cohort subset 
has been satisfied . The enrollment cap for the exercise challenges will follow a 
similar logic as above f or total enrollment and will be detailed in the Statistical 
Analysis Plan.  
13.4 Analysis Sets  
The following analysis sets are planned for the study  and will apply to the 
endpoints through the end of Phase 2.  There are no prespecified analysis sets for 
Phase 3;  all available data will be used to summarize Phase 3 endpoints : 
13.4.1  ITT (Intention to Treat)  Analysis Set  
The ITT analysis set includes all subjects that are enrolled in the study. All safety 
analyses (other than primary analysis of primary safety endpoints) will be based 
on the ITT analysis set.  
13.4.2  mITT ( modified Intention to Treat)  Analysis Set  
The modified Intention to Treat (mITT) analysis set is a subset of the ITT analysis 
set. The mITT analysis set  will consist of subjects  who have entered the hybrid 
close d-loop phase of the study  successfully.  The mITT analysis set  will be used as 
the primary analysis for the primary and secondary endpoints an d other clinical 
outcome data.  
13.4.3  PP (Per -Protocol)  Analysis Set  
The Per -Protocol (PP)  analysis set  is a subset of the mITT analysis set. Subjects  
will be included in the PP analysis set  if they have a minimum of 80% system use 
during the hybrid closed -loop phase inclusive of Manual and hybrid closed -loop 
(Automated ) modes over a minimum duration of [ADDRESS_48531] completed 
the study without major protocol deviations.  The Manual Mode use during study 
pause does not contribute to the minimum system use requirement.  The PP 
analysis set  will be used as supportive analysis for the endpoints . The following  
will be considered major protocol deviations:  
• Major inclusion/exclusion criterion deviation  
• Significant protocol non -compliance that may confound the study objective 
data (e.g., use of prohibited medications ) 
The list of subjects excluded from the PP analysis set will be determined prior to 
analysis. If the PP analysis set does not differ from the mITT analysis set, 
separate analyses will not be presented.  
13.[ADDRESS_48532] at a one -sided significance 
level of 1.25%.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48533] one of the  Phase 2  primary effectiveness endpoints are found to be 
significant, the testing for Phase 2 secondary  endpoints can commence. The 
details on how the family -wise error rate will be maintained at the 2.5% 
significance level (one -sided) will be provided in the Statistical Analysis Plan 
(SAP). In addition, the Phase 2 primary effectiveness endpoints may also be 
tested for significance within a smaller cohort of subjects (such as based on age). 
The details of subgroup analyses and testing will also be detailed in the SAP.  At a 
minimum, the Phase 2 primary effectiveness endpoints will be presented by 
[CONTACT_45965] G6 use at the time of screening (users and non -users) and by 
[CONTACT_45966][INVESTIGATOR_2397] (those who participated in the prepi[INVESTIGATOR_45900]).  
There are no hypotheses associated with the other Phase [ADDRESS_48534] (e.g., day vs. night, 
overall). The Phase 2 primary and secondary endpoints will be summarized for 
modified Intention  to Treat (mITT) and Per Protocol (PP) analysis sets. If the PP 
analysis set does not differ from the mITT analysis set, separate analyses will not 
be presented. The data may be stratified by [CONTACT_45967], where the data 
collected in the standard the rapy phase of the study will be compared to the data 
collected in the hybrid closed -loop phase of the study.  
13.5.1  Time in Range Endpoints  
The primary effectiveness endpoint and the secondary endpoints that summarize 
time in specific glycemic ranges will be cal culated from device data outputs as 
follows:  
100 ×# 𝑜𝑓 𝐶𝐺𝑀  𝑟𝑒𝑐𝑜𝑟𝑑𝑠  𝑖𝑛 𝑟𝑎𝑛𝑔𝑒  
# 𝑜𝑓 𝑒𝑣𝑎𝑙𝑢𝑎𝑏𝑙𝑒  𝐶𝐺𝑀  𝑟𝑒𝑐𝑜𝑟𝑑𝑠=𝑇𝐼𝑅% 
13.[ADDRESS_48535] safety and measures may be 
taken to address the issue such as, but not limited to, changes to the protocol 
and/or device. Any resulting device deficiencies will be reported, if applicable. A 
brief summary of the controller data rev iews will be included in the final clinical 
study report.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 72 
13.7 Safety Analyses  
13.7.1  Evaluation of Adverse Events  
All adverse events reported over the course of the study will be summarized and 
tabulated by  [CONTACT_45968], event category, seriousness, severity , and rel ationship 
to the study  procedure  and the investigational device. For the purposes of 
summarization, an event will be considered “ Related” if the relationship was 
deemed as “Possibly Related” or “Related”. In cases where the same event is 
reported more than  once per subject, the event will only be counted once in the 
incidence table(s).   
Adverse events leading to death or to discontinuation from the study will be listed 
separately.  A listing of all adverse events will be provided.  The primary safety 
endpoints will be presented by [CONTACT_45969] G6 use at the time of screening 
(users and non -users) and by [CONTACT_45966][INVESTIGATOR_2397] (those who 
participated in the prepi[INVESTIGATOR_45901] l study and those who did not).  
Adverse events that were reported during study pause will be listed separately.  
13.7.[ADDRESS_48536] (such as age, gender, medical history, etc.) will be presented. Data on all 
enrolled subjects will be presented. Continuous variable s will be summarized 
using count, mean, median, standard deviation, and range. Categorical variables 
will be summarized using counts and percentages.  
13.[ADDRESS_48537]  data listings. 
Unless otherwise noted, all p -values will be considered significant at a two -sided 
significance level of 5%. Continuous variables will be summarized using 
descript ive stati stics, including count , mean, median, standard deviation (SD), 
minimum and maximum. Where appropriate, 95% two -sided confidence intervals 
for the means or medians will be presented. If the observed data are found not to 
follow a normal distribution, approp riate non -parametric methods may be 
employed. Categorical variables will be summarized by [CONTACT_45970]. Unless explicitly stated otherwise, percentages will utilize a 
denominator corresponding to the number of unique subjects . 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 73 
13.10  Missing D ata 
All practical monitoring and follow -up steps will be taken to ensure complete and 
accurate data collection.  All analys es will be based on available data only; no 
imputation for missing data is planned . 
13.11  Statistical Software  
The statistical software package SAS® 9. 4 or later will be used for all the data 
derivations, summarization, data listings and statistical analyses. Addit ional 
software such as Splus or R may be used for graphics or validation as 
appropriate.  
Additional details regarding statistical analyses will be provided in the Statistical 
Analysis Plan  (SAP) which will be prepared prior to data analysis. If discrepanci es 
exist between the protocol and the SAP, the SAP will prevail. Any deviations from 
the finalized SAP will be described in the final study report . 
14 DATA HANDLING  AND QUALITY ASSURANCE  
Data in this study will be collected on Electronic Case Report Forms as well as via 
electronic device outputs . 
14.1 Electronic Case Report Forms  (eCRFs)  
Study data are collected through a combination of subject electronic CRFs 
(eCRFs) and electronic device data files.  eCRF Data will be recorded in a [ADDRESS_48538] be reviewed  and signed  
by [CONTACT_941] i nvestigator in the EDC system . The investigator also agrees to maintain 
accurate source documentation supporting the data . When pertinent supportive 
information is available for data entered dir ectly into the eCRFs, this supporting 
documentation will also be maintained. S ource documents may include chart 
notes, laboratory reports, images , study specific source worksheets, eCRFs, 
device data files, etc. 
14.2 Electronic Device Outputs  
14.2.1  PDM Data  
This stud y will utilize insulin delivery data from the PDM device . All insulin delivery 
data and all CGM readings from the hybrid closed -loop phase will be stored on the 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48539] ’s name.  
14.[ADDRESS_48540] of monitoring visits as well  as identify any 
relevant study -specific monitoring responsibilities.  
Monitor s for this study will be qualified by [CONTACT_8640], experience and training.  The 
monitor  will report to the Spons or any non -compliance with the protocol, 
applicable regulations , or any conditions  imposed by [CONTACT_32629] B or local regulatory 
authority.  If compliance cannot be secured, device shipments to the Investigator 
may be discontinued and the Investigator’s participat ion in the study  terminated.  
Investigators and clinical site coordinators are expected to make source files and 
other records and reports available to the monitors  as required . 
14.[ADDRESS_48541] copi[INVESTIGATOR_45902] . 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48542] remain on file at the investigational site for a minimum 
of two years after the later of either the completion/termination of the study or the 
date of market approval for the indication being studied. They may be discarded 
only upo n approval from the Sponsor. The Principal Investigator [INVESTIGATOR_45903]. In addition, the Sponsor  must be 
contact[CONTACT_45971] a new investigator or records transfer are made prior to 
investigator departure . 
14.[ADDRESS_48543] be stored according to the conditions set forth for the device 
on the label  in a controlled, locked area. All device shipment records (packing 
lists, etc.) must be maintained at the clinical site.  
The study monitor will verify accountability of the study devices during routine 
monitoring visits to the clinical site.  
[ADDRESS_48544] 
Research Organization ( CRO ). 
15.[ADDRESS_48545] of the Study  
The investigat ion will be conducted according to the applicable FDA regulations 
(21CFR  812, 56, 54, 50 ). The investigator will conduct all aspects of this study in 
accordance with all state, and local laws or regulations.  
15.[ADDRESS_48546]  (IRB)  
Federal regulation s (21 CFR 812) require that approval be obtained from an IRB 
prior to participation of subject s in research studies. Prior to subject  enrollment, a 
signed copy of the IRB approval letter must be submitted to the Sponsor . In 
addition , the protocol, informed consent, advertisements to be used for subject  
recruitment, and any other written information regarding this study to be provided 
to the subject  must be approved by [CONTACT_1201].  Documentation of all IRB approvals 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48547] 
identify the IRB by [CONTACT_45972], the clinical protocol by [CONTACT_29985]/or protocol 
number, a nd the date approval was granted.  
The Investigator is responsible for submitting and obtaining initial and continuing  
review of the trial at intervals not exceeding [ADDRESS_48548] . An informed consent  form (ICF) 
template will be provided by [CONTACT_45973]. 
If any institution -specific modifications to study -related procedures are proposed 
or made by [CONTACT_45974], the consent must  be reviewed by [CONTACT_45975]. Once reviewed, the consent will be submitted by [CONTACT_45976].  
Before recruitment and enrollment, each prospective subject  will be given a full 
explanation of the study and be allowed to read the approved ICF. Once the 
investigator  or designee  is assured that the subject  understands the implications 
of participating in the study, the subject  will be asked to give consent to p articipate 
in the study by [CONTACT_12568]. 
The investigator or designee shall provide a copy of the signed ICF to the subject . 
The original form shall be maintained in the subject  binder  at the clinical site. 
15.[ADDRESS_48549] -protecte d computers .  
This includes , but is not limited to the following:  
• Subject s will be identified on all eCRFs by a unique subject  ID 
• eCRFs are confidential documents and will only be available to the Sponsor  
(including delegates, such as CRAs), DSMB, Medical Monitor, CRO, the 
investigator  and study staff , and if requested, to  the IRB or  regulatory 
authorities. The investigator will maint ain, as part of the investigation file, a 
list identifying all subject s entered into the study . 
All laboratory specimens, evaluation forms, reports, and other records will be 
identified in a manner designed to maintain subject  confidentiality. Clinical 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48550] , 
except as necessary for monitoring and auditing by [CONTACT_1034] , its designee, the 
FDA, or the IRB.  
The investigator and all clinical site staff involved in this study may not disclose (or 
use for any purpose other than performance of the study ), any data, record, or 
other unpublished confidential information disclosed to those individuals for the 
purpose of the study. Prior written agreement from the Sponsor  or its designee 
must be obtained for the disclosure of any said confidential information to other 
parties.  
15.[ADDRESS_48551] be reviewed and approved by [CONTACT_429] . The protocol amendment(s) must be signed by [CONTACT_45977]. The protocol amendment (s) will be 
filed with the appropriate regulatory agency(s) having jurisdiction ov er the conduct 
of the study.  
Substantial changes will require approval from the Sponsor , FDA, and IRB prior to 
implementation.  
15.[ADDRESS_48552] ’s risk 
or affect the validity of the trial. In medical emergencies, prior approval for protocol 
deviations will not be required, but t he Sponsor  must be notified within [ADDRESS_48553] ’s source documentation. The IRB should be notif ied of all protocol 
deviations in a timely manner. Protocol deviations should be reported to the IRB 
periodically, according to their requirements. Deviations will also be reviewed  by 
[CONTACT_45978].  
The Sponsor  will evaluate circumstances where the investigator deviates from the 
study  protocol and will retain the right to remove either the investigator or the 
inves tigational clinical site from the study.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 78 
15.8 Study Reporting Requirements  
By [CONTACT_4907], the investigator agrees to submit SAE reports 
according to the timeline and method outlined in  this protocol.  In addition, the 
investigator agrees to submit a nnual reports to his/her IRB  as appropriate . 
Upon completion or termination of the study , the principal investigator (PI) must 
submit a final written report to the Sponsor  and IR B. The report must be submitted 
within 3 months (90 days) of completion or termination of the trial.  
The Sponsor  will submit all reports required by [CONTACT_45979], including unanticipated adverse device effects, withdrawal of IRB 
approval, list of current investigators , annual progress reports, recall information, 
final r eports and protocol deviations . 
15.[ADDRESS_48554] qualified investigators, ship devices only to participating 
investigators, obtain a signed Investigator’s Agreement and provide all 
investigators with the information and training necessary to conduct the study.  
15.9.[ADDRESS_48555] notify the Spons or promptly o f any relevant changes that occur during the 
course of the study , at the completion of the study , and 1 year following the 
completion of the study.  
15.9.2  Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comp ly with 21 CFR 
812 by [CONTACT_44074], including but not limited to:  
• An investigator -signed Investigator Agreement page of the protocol  
• An IRB approved informed consent, samples of clinical site advertisements 
for recruitment for this study, and any other written information regarding this 
study that is to be provided to the subject  
• IRB approval of the investigator, protocol, and acknowledgement of the user 
guide  
• Curricula vitae (CV) for the PI [INVESTIGATOR_45904] . Current licensure must be noted on the CV or a copy of the license 
provided . CVs must be signed and dated by [CONTACT_45980] 1 year of 
study start -up, indicating that they are accurate and curre nt. 
• Financial disclosure information  (as stated above) and a commitment to 
promptly update this information if any relevant changes occur  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 79 
• Laboratory certifications and normal ranges for any local laboratories used 
by [CONTACT_977]. 
15.[ADDRESS_48556]  care.  
15.11  Device Use 
The Omnipod Horizon ™ System  consist s of the following primary components : 
an Omnipod  Horizon™ Pod, Omnipod Horizon™ Controller , and the iCGM . 
The Pod  and PDM are  intended for single use only .  The PDMs will be returned 
to the Sponsor after completion of the study.  
The Dexcom G6 CGM sensor (the component of the system that enters the 
skin) , the Dexcom G6 CGM transmitter (the component of the system that 
attaches to  the sensor to transmit the signal) , and the Dexcom G6 CGM receiver  
will all be single use only  in this study . The Dexcom G6 receiver will be returned 
to the Sponsor after completion of the study.  
Study blood glucose meters and ketone meters  will not be cleaned or reused by 
[CONTACT_1766]. A new meter will be used  for each subject.  
15.[ADDRESS_48557] the Sponsor  
representative and provide the following information:  
• Part number/Lot number  
• Quantities  
• Tracking number  
15.13  Policy for P ublicat ion and Presentati on of D ata 
All data and results and all intellectual property rights in the data and results 
derived from the study will be the property of the study Sponsor , Insulet .  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | [ADDRESS_48558]  follow -
up shall be reported on the eCRF . 
  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 81 
REFERENCES  
1. Centers for Disease Control and Prevention. “Diabetes Report Card 2012” Atlanta, GA: 
Centers for Disease Control and Prevention, US Department of Health and Human Services 
(2012).  
2. Nathan, DM et al. “Intensive diabetes treatment and cardiovascular disease in patients with 
type 1 diabetes”. N. Engl. J. Med. 353: 2643 -2653 (2005).  
3. Cryer, PE “Banting lect ure. Hypoglycemia: the limiting factor in the management of IDDM”. 
Diabetes 43: 1378 -1389, (1994).  
4. Weinstock RS et al. “Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 
diabetes: results from the T1D Exchange clinic registry ” J Clin Endo crinol Metab.  
98(8):3411 -3419 (2013).  
5. Livingstone SJ et al. “Estimated life expectancy in a Scottish cohort with type 1 diabetes 
2008 -2010”. JAMA . Jan 6;313(1):37 -44 (2015).  
6. Lind M et al. “Glycemic control and excess mortality in type 1 diabetes”. N Engl J  Med. 
20;371(21):1972 -1978 (2014).  
7. American Diabetes Association “Treatment Guidelines: Children and adolescents”. Diabetes 
Care  2015;38 (Suppl.):S70 -S76 (2015).  
8. Nathan DM et al., “Translating the A1C assay into estimated average glucose values” 
Diabetes 31:1-6 (2008).  
9. Beck RW et al., “The T1D Exchange clinic registry“ J Clin Endocrinol Metab. 97(12):4383 -
4389 (2012).  
10. Foster NC  et al., “ State of Type 1 Diabetes Management and Outcomes from the T1D 
Exchange in 2016 -1018 ” Diabetes Technology Ther . Volume 21(2) pp. 66 -72 (2019). 
11. Beck SE, “The content of Investigational Device Exemption and Premarket Approval (PMA) 
applications for Artificial Pancreas Device Systems” UCM259305 (November 9, 2012).  
12. Centers for Disease Control and Prevention – Physical A ctivity Basics: 
https://www.cdc.gov/physicalactivity/basics/index.htm?CDC_AA_refVal=https% 3A%2F%2F
www.cdc.gov%2Fphysicalactivity%2Fbasics%2Fmeasuring%2Fheartrate.htm  
13. Buckingham B, Pi[INVESTIGATOR_45905], Christiansen M, Schneider J, Peyser T, Dassau E, Lee JB, 
O'Connor J, Layne JE, Ly TT. Feasibility of Omnipod Hybrid Closed -loop Control in Adults 
With Typ e 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes 
Technol Ther.  2017;19(S1):A18 -A19.  
14. Buckingham B, Forlenza GP, Schneider J, Peyser T, Dassau E, Lee JB, O'Connor J, Layne 
JE, Ly TT. Safety and Feasibility of Omnipod Hybrid Clos ed-Loop in Children Aged 6 -12 
Years with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. 
Diabetes . 2017;66(S1A):LB34.  
15. Buckingham B, Forlenza GP, Schneider J, Peyser T, Dassau E, Lee JB, O'Connor J, Layne 
JE, Ly TT. Safety and Feasi bility of Omnipod Hybrid Closed -Loop in Adolescents with Type 
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 82 
1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes . 
2017;66(S1):A278.  
16. Forlenza GP, Buckingham B, Christiansen M, Wadwa RP, Peyser T, Lee JB, O'Connor J, 
Dassau E, Layne  JE, Ly TT. Performance of Omnipod Personalized Model Predictive 
Control Algorithm With Moderate Intensity Exercise and Variable Setpoints in Adults With 
Type 1 Diabetes. Diabetes Technol Ther.  2018;20(S1):A56 -A57.  
17. Buckingham B, Christiansen M, Forlenza GP , Wadwa RP, Peyser T, Lee JB, O'Connor J, 
Dassau E, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive 
Control Algorithm With Specific Meal Challenges in Adults With Type 1 Diabetes. Diabetes 
Technol Ther . 2018;20(S1):A12 -A13. 
18. Buckingham  BA, Christiansen MP, Forlenza GP, Wadwa RP, Peyser TA, Lee JB, O'Connor 
J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of the Omnipod Personalized Model 
Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. 
Diabetes  Technol Ther.  2018;20(9):585 -595. 
19. Buckingham BA, Forlenza GP, Pi[INVESTIGATOR_45905], Christiansen MP, Wadwa RP, Schneider J, 
Peyser TA, Dassau E, Lee JB, O'Connor J, Layne JE, Ly TT. Safety and feasibility of the 
OmniPod  hybrid closed -loop system in adult, adolescent, and pediatric patients with type 1 
diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther.  
2018;20(4):257 -262. 
20. Buckingham B, Sherr J, Forlenza GP, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed -Loop System Over 
5 Days of Outpatient Use in Adults with Type 1 Diabetes. Diabetes . 2018;67(S1):A55.  
21. Forlenza GP, Buckingham B, Sherr J, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed -Loop System in 
Adolescents with Type 1 Diabetes Over 5 Days Under Free -Living Conditions. Diabetes . 
2018;67(S1):A369.  
22. Sherr J, Forlenza GP, Buckingham B, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed -Loop System in 
Children with Type 1 Diabetes Over 5 Days Under Free -Living Conditi ons. Diabetes . 
2018;67(S1):A369.  
23. Forlenza GP, Buckingham BA, Christiansen MP, et al. Performance of Omnipod 
Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults 
with Type [ADDRESS_48559] of intensive 
treatment of diabetes on the development and progression of long -term complications in 
insulin -dependent diabetes mellitus. N Engl J Med 1993;329:[ADDRESS_48560] WV, T1D Exchange Clinic Network. Current state of type 1 diabetes treatment 
in the US: updated data from the  T1D Exchange clinic registry. Diabetes Care. 
2015;38(6):971 -8 
27. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 
2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018.  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 83 
28. ISO [ZIP_CODE]:2011 (E), Cl inical investigation of medical devices for human subjects – Good 
clinical practice, second edition 2011 -02-01. 
29. Sherr J, Buckingham BA, Forlenza G, et al. Safety and Performance of the Omnipod Hybrid 
Closed -Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 
Days Under Free -Living Conditions. Diabetes Technol Ther. 2019.  
 
  
   
Omnipod  
Horizon™ Pi[INVESTIGATOR_45860] V5.0  Confidential  Page | 84 
APPENDIX  A 
 
 
